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Guidelines for the management of patients with invasive candidiasis and mucosal candidiasis were prepared
by an Expert Panel of the Infectious Diseases Society of America. These updated guidelines replace the previous
guidelines published in the 15 January 2004 issue of Clinical Infectious Diseases and are intended for use by
health care providers who care for patients who either have or are at risk of these infections. Since 2004,
several new antifungal agents have become available, and several new studies have been published relating to
the treatment of candidemia, other forms of invasive candidiasis, and mucosal disease, including oropharyngeal
and esophageal candidiasis. There are also recent prospective data on the prevention of invasive candidiasis
in high-risk neonates and adults and on the empiric treatment of suspected invasive candidiasis in adults.
This new information is incorporated into this revised document.
EXECUTIVE SUMMARY
There have been several significant changes in the man-
agement of candidiasis since the last publication of
these guidelines in January 2004. Most of these changes
relate to the appropriate use of echinocandins and ex-
panded spectrum azoles in the management of can-
didemia, other forms of invasive candidiasis, and mu-
cosal candidiasis. For some of the less common forms
of invasive candidiasis (e.g., chronic disseminated can-
didiasis, osteomyelitis, and CNS disease), there are few
new treatment data since 2004, with only anecdotal
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experience, case reports, or small series providing some
evidence to support new approaches to therapy. Each
section of the Guideline begins with a specific clinical
question and is followed by numbered recommenda-
tions and a summary of the most-relevant evidence in
support of the recommendations. The most significant
changes and/or additions to existing recommendations
are described below in the Executive Summary. The
remaining topics are discussed in greater detail in the
main body of the guidelines.
Candidemia in Nonneutropenic Patients
• Fluconazole (loading dose of 800 mg [12 mg/kg],
then 400 mg [6 mg/kg] daily) or an echinocandin
(caspofungin: loading dose of 70 mg, then 50 mg
daily; micafungin: 100 mg daily; anidulafungin: load-
ing dose of 200 mg, then 100 mg daily) is recom-
mended as initial therapy for most adult patients (A-
I). The Expert Panel favors an echinocandin for
patients with moderately severe to severe illness or
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for patients who have had recent azole exposure (A-III). Flu-
conazole is recommended for patients who are less critically
ill and who have had no recent azole exposure (A-III). The
same therapeutic approach is advised for children, with at-
tention to differences in dosing regimens.
• Transition from an echinocandin to fluconazole is recom-
mended for patients who have isolates that are likely to be
susceptible to fluconazole (e.g.,Candida albicans) and who
are clinically stable (A-II).
• For infection due to Candida glabrata, an echinocandin is
preferred (B-III). Transition to fluconazole or voriconazole
therapy is not recommended without confirmation of isolate
susceptibility (B-III). For patients who have initially received
fluconazole or voriconazole, are clinically improved, and
whose follow-up culture results are negative, continuing use
of an azole to completion of therapy is reasonable (B-III).
• For infection due to Candida parapsilosis, treatment with
fluconazole is recommended (B-III). For patients who have
initially received an echinocandin, are clinically improved,
and whose follow-up culture results are negative, continuing
use of an echinocandin is reasonable (B-III).
• Amphotericin B deoxycholate (AmB-d) administered at a
dosage of 0.5–1.0 mg/kg daily or a lipid formulation of AmB
(LFAmB) administered at a dosage of 3–5 mg/kg daily are
alternatives if there is intolerance to or limited availability of
other antifungals (A-I). Transition from AmB-d or LFAmB
to fluconazole is recommended for patients who have isolates
that are likely to be susceptible to fluconazole (e.g., C. al-
bicans) and who are clinically stable (A-I).
• Voriconazole administered at a dosage of 400 mg (6 mg/kg)
twice daily for 2 doses and then 200 mg (3mg/kg) twice daily
thereafter is effective for candidemia (A-I), but it offers little
advantage over fluconazole and is recommended as step-
down oral therapy for selected cases of candidiasis due to
Candida krusei or voriconazole-susceptible C. glabrata (B-
III).
• The recommended duration of therapy for candidemia with-
out obvious metastatic complications is for 2 weeks after
documented clearance of Candida from the bloodstream and
resolution of symptoms attributable to candidemia (A-III).
• Intravenous catheter removal is strongly recommended for
nonneutropenic patients with candidemia (A-II).
Candidemia in Neutropenic Patients
• An echinocandin (caspofungin: loading dose of 70 mg, then
50 mg daily; micafungin: 100 mg daily [A-II]; anidulafungin:
loading dose of 200 mg, then 100 mg daily [A-III]) or LFAmB
(3–5 mg/kg daily [A-II]) is recommended for most patients.
• For patients who are less critically ill and who have no recent
azole exposure, fluconazole (loading dose of 800 mg [12 mg/
kg], then 400 mg [6 mg/kg] daily) is a reasonable alternative
(B-III). Voriconazole can be used in situations in which ad-
ditional mold coverage is desired (B-III).
• For infections due to C. glabrata, an echinocandin is preferred
(B-III). LFAmB is an effective but less attractive alternative
(B-III). For patients who were already receiving voriconazole
or fluconazole, are clinically improved, and whose follow-up
culture results are negative, continuing use of the azole to
completion of therapy is reasonable (B-III).
• For infections due to C. parapsilosis, fluconazole or LFAmB
is preferred as initial therapy (B-III). If the patient is receiving
an echinocandin, is clinically stable, and follow-up culture
results are negative, continuing the echinocandin until com-
pletion of therapy is reasonable. For infections due to C.
krusei, an echinocandin, LFAmB, or voriconazole is recom-
mended (B-III).
• Recommended duration of therapy for candidemia without
persistent fungemia or metastatic complications is for 2 weeks
after documented clearance of Candida from the blood-
stream, resolution of symptoms attributable to candidemia,
and resolution of neutropenia (A-III).
• Intravenous catheter removal should be considered (B-III).
Empirical Treatment for Suspected Invasive Candidiasis in
Nonneutropenic Patients
• Empirical therapy for suspected candidiasis in nonneutro-
penic patients is similar to that for proven candidiasis. Flu-
conazole (loading dose of 800 mg [12mg/kg], then 400 mg
[6 mg/kg] daily), caspofungin (loading dose of 70 mg, then
50 mg daily), anidulafungin (loading dose of 200 mg, then
100 mg daily), or micafungin (100 mg daily) is recommended
as initial therapy (B-III). An echinocandin is preferred for
patients who have had recent azole exposure, whose illness
is moderately severe or severe, or who are at high risk of
infection due to C. glabrata or C. krusei (B-III).
• AmB-d (0.5–1.0 mg/kg daily) or LFAmB (3–5 mg/kg daily)
are alternatives if there is intolerance to other antifungals or
limited availability of other antifungals (B-III).
• Empirical antifungal therapy should be considered for crit-
ically ill patients with risk factors for invasive candidiasis and
no other known cause of fever, and it should be based on
clinical assessment of risk factors, serologic markers for in-
vasive candidiasis, and/or culture data from nonsterile sites
(B-III).
Empirical Treatment for Suspected Invasive Candidiasis in
Neutropenic Patients
• LFAmB (3–5 mg/kg daily), caspofungin (loading dose of 70
mg, then 50 mg daily) (A-I), or voriconazole (6 mg/kg ad-
ministered intravenously twice daily for 2 doses, then 3 mg/
kg twice daily) are recommended (B-I).
• Fluconazole (loading dose of 800 mg [12 mg/kg], then 400
mg [6 mg/kg] daily) and itraconazole (200 mg [3mg/kg] twice
daily) are alternative agents (B-I).
• AmB-d is an effective alternative, but there is a higher risk
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of toxicity with this formulation than with LFAmB (A-I).
• Azoles should not be used for empirical therapy in patients
who have received an azole for prophylaxis (B-II).
Treatment for Neonatal Candidiasis
• AmB-d (1 mg/kg daily) is recommended for neonates with
disseminated candidiasis (A-II). If urinary tract involvement
is excluded, LFAmB (3–5 mg/kg daily) can be used (B-II).
Fluconazole (12 mg/kg daily) is a reasonable alternative (B-
II). The recommended length of therapy is 3 weeks (B-II).
• A lumbar puncture and a dilated retinal examination, pref-
erably by an ophthalmologist, are recommended in neonates
with sterile body fluid and/or urine cultures positive for Can-
dida species (B-III). Imaging of the genitourinary tract, liver,
and spleen should be performed if the results of sterile body
fluid cultures are persistently positive (B-III).
• Echinocandins should be used with caution and are generally
limited to situations in which resistance or toxicity precludes
the use of fluconazole or AmB-d (B-III).
• Intravascular catheter removal is strongly recommended (A-
II).
• In nurseries with high rates of invasive candidiasis, flucon-
azole prophylaxis may be considered in neonates whose birth
weight is !1000 g (A-I). Antifungal drug resistance, drug-
related toxicity, and neurodevelopmental outcomes should
be observed (A-III).
Antifungal Prophylaxis for Solid-Organ Transplant Recipients,
Patients Hospitalized in Intensive Care Units (ICUs),
Neutropenic Patients receiving Chemotherapy, and Stem Cell
Transplant Recipients at Risk of Candidiasis
• For solid-organ transplant recipients, fluconazole (200–400
mg [3–6 mg/kg] daily) or liposomal AmB (L-AmB) (1–2 mg/
kg daily for 7–14 days) is recommended as postoperative
antifungal prophylaxis for liver (A-I), pancreas (B-II), and
small bowel (B-III) transplant recipients at high risk of
candidiasis.
• For patients hospitalized in the ICU, fluconazole (400 mg [6
mg/kg] daily) is recommended for high-risk patients in adult
units that have a high incidence of invasive candidiasis (B-
I).
• For patients with chemotherapy-induced neutropenia, flu-
conazole (400 mg [6 mg/kg} daily) (A-I), posaconazole (200
mg 3 times daily) (A-I), or caspofungin (50 mg daily) (B-
II) is recommended during induction chemotherapy for the
duration of neutropenia. Oral itraconazole (200 mg twice
daily) is an effective alternative (A-1), but it offers little ad-
vantage over other agents and is less well tolerated.
• For stem cell transplant recipients with neutropenia, flucon-
azole (400 mg [6 mg/kg] daily), posaconazole (200 mg 3
times daily), or micafungin (50 mg daily) is recommended
during the period of risk of neutropenia (A-I).
INTRODUCTION
Candida species are the most common cause of invasive fungal
infections in humans, producing infections that range from
non–life-threatening mucocutaneous disorders to invasive dis-
ease that can involve any organ. Invasive candidiasis is largely
a disease of medical progress, reflecting the tremendous ad-
vances in health care technology over the past several decades
[1–5]. The most frequently implicated risk factors include the
use of broad-spectrum antibacterial agents, use of central ve-
nous catheters, receipt of parenteral nutrition, receipt of renal
replacement therapy by patients in ICUs, neutropenia, use of
implantable prosthetic devices, and receipt of immunosup-
pressive agents (including glucocorticosteroids, chemothera-
peutic agents, and immunomodulators) [2–7]. Candidemia is
the fourth most common cause of nosocomial bloodstream
infections in the United States and in much of the developed
world [5, 8–10]. Invasive candidiasis has a significant impact
on patient outcomes, and it has been estimated that the at-
tributable mortality of invasive candidiasis is as high as 47%
[11], although many authorities estimate the attributable mor-
tality to be 15%–25% for adults and 10%–15% for neonates
and children [12, 13]. The estimated additional cost of each
episode of invasive candidiasis in hospitalized adults is
∼$40,000 [1, 13].
The Expert Panel addressed the following clinical questions:
I. What is the treatment of candidemia in nonneutropenic
patients?
II. What is the treatment of candidemia in neutropenic
patients?
III. What is the empirical treatment for suspected invasive
candidiasis in nonneutropenic patients?
IV. What is the empirical treatment for suspected invasive
candidiasis in neutropenic patients?
V. What is the treatment for urinary tract infections due to
Candida species?
VI. What is the treatment for vulvovaginal candidiais?
VII. What is the treatment for chronic disseminated
candidiasis?
VIII. What is the treatment for osteoarticular infections due
to Candida species?
IX. What is the treatment for CNS candidiasis in adults?
X. What is the treatment for Candida endophthalmitis?
XI. What is the treatment for infections of the cardiovascular
system due to Candida species?
XII. What is the treatment for neonatal candidiasis?
XIII. What is the significance of Candida species isolated
from respiratory secretions?
XIV. What is the treatment for nongenital mucocutaneous
candidiasis?
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Table 1. Infectious Diseases Society of America–US Public Health Service Grading System for
ranking recommendations in clinical guidelines.
Category, grade Definition
Strength of recommendation
A Good evidence to support a recommendation for or against use
B Moderate evidence to support a recommendation for or against use
C Poor evidence to support a recommendation
Quality of evidence
I Evidence from 1 properly randomized, controlled trial
II Evidence from 1 well-designed clinical trial, without randomiza-
tion; from cohort or case-controlled analytic studies (preferably
from 11 center); from multiple time-series; or from dramatic re-
sults from uncontrolled experiments
III Evidence from opinions of respected authorities, based on clinical
experience, descriptive studies, or reports of expert committees
NOTE. Adapted from Canadian Task Force on the Periodic Health Examination [15].
XV. Should antifungal prophylaxis be used for solid-organ
transplant recipients, ICU patients, neutropenic patients re-
ceiving chemotherapy, and stem cell transplant recipients at
risk of candidiasis?
PRACTICE GUIDELINES
Practice guidelines are systematically developed statements to
assist practitioners and patients in making decisions about ap-
propriate health care for specific clinical circumstances [14].
Attributes of good guidelines include validity, reliability, re-
producibility, clinical applicability, clinical flexibility, clarity,
multidisciplinary process, review of evidence, and documen-
tation [14].
UPDATE METHODOLOGY
Panel Composition
The Infectious Diseases Society of America (IDSA) Standards
and Practice Guidelines Committee (SPGC) convened experts
in the management of patients with candidiasis. The specialties
of the members of the Expert Panel are listed at the end of the
text.
Literature Review and Analysis
For the 2009 update, the Expert Panel completed the review
and analysis of data published since 2004. Computerized lit-
erature searches of the English-language literature using
PubMed were performed.
Process Overview
In evaluating the evidence regarding the management of can-
didiasis, the Expert Panel followed a process used in the de-
velopment of other IDSA guidelines. The process included a
systematic weighting of the quality of the evidence and the
grade of recommendation (table 1) [15].
Consensus Development on the Basis of Evidence
The Expert Panel met in person on 1 occasion and via tele-
conference 11 times to discuss the questions to be addressed,
to make writing assignments, and to deliberate on the rec-
ommendations. All members of the Expert Panel participated
in the preparation and review of the draft guidelines. Feedback
from external peer reviews was obtained. The guidelines were
reviewed and approved by the IDSA SPGC and the IDSA Board
of Directors prior to dissemination. A summary of the rec-
ommendations is included in table 2.
Guidelines and Conflict of Interest
All members of the Expert Panel complied with the IDSA policy
on conflicts of interest, which requires disclosure of any finan-
cial or other interest that might be construed as constituting
an actual, potential, or apparent conflict. Members of the
Expert Panel were provided with the IDSA’s conflict of interest
disclosure statement and were asked to identify ties to com-
panies developing products that might be affected by prom-
ulgation of the guidelines. Information was requested regarding
employment, consultancies, stock ownership, honoraria, re-
search funding, expert testimony, and membership on company
advisory committees. The Expert Panel made decisions on a
case-by-case basis as to whether an individual’s role should be
limited as a result of a conflict. Potential conflicts of interest
are listed in the Acknowledgments section.
Revision Dates
At annual intervals, the Expert Panel Chair, the SPGC liaison
advisor, and the Chair of the SPGC will determine the need
for revisions to the guidelines on the basis of an examination
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of current literature. If necessary, the entire Expert Panel will
be reconvened to discuss potential changes. When appropriate,
the Expert Panel will recommend revision of the guidelines to
the SPGC and the IDSA Board for review and approval.
LITERATURE REVIEW
Pharmacologic Considerations of Therapy for Candidiasis
Systemic antifungal agents shown to be effective for the treat-
ment of candidiasis comprise 4 major categories: the polyenes
(AmB-d, L-AmB, AmB lipid complex [ABLC], and AmB col-
loidal dispersion [ABCD]), the triazoles (fluconazole, itracon-
azole, voriconazole, and posaconazole), the echinocandins (cas-
pofungin, anidulafungin, and micafungin), and flucytosine.
Clinicians should become familiar with strategies to optimize
efficacy through an understanding of relevant pharmacokinetic
properties.
Amphotericin B (AmB)
Most experience with AmB is with the deoxycholate prepara-
tion (AmB-d). Three LFAmBs have been developed and ap-
proved for use in humans: ABLC, ABCD, and L-AmB. These
agents possess the same spectrum of activity as AmB-d. The 3
LFAmBs have different pharmacological properties and rates
of treatment-related adverse events and should not be inter-
changed without careful consideration. In this document, a
reference to AmB, without a specific dose or other discussion
of form, should be taken to be a reference to the general use
of any of the AmB preparations. For most forms of invasive
candidiasis, the typical intravenous dosage for AmB-d is 0.5–
0.7 mg/kg daily, but dosages as high as 1 mg/kg daily should
be considered for invasive Candida infections caused by less
susceptible species, such as C. glabrata and C. krusei. The typical
dosage for LFAmB is 3–5 mg/kg daily when used for invasive
candidiasis [16, 17]. Nephrotoxicity is the most common se-
rious adverse effect associated with AmB-d therapy, resulting
in acute renal failure in up to 50% of recipients [18]. LFAmBs
are considerably more expensive than AmB-d, but all have
considerably less nephrotoxicity [19–21]. These agents retain
the infusion-related toxicities associated with AmB-d. Among
these agents, a comparative study suggests that L-AmB may
afford the greatest renal protection [21]. The impact of the
pharmacokinetics and differences in toxicity of LFAmB has not
been formally examined in clinical trials. We are not aware of
any forms of candidiasis for which LFAmB is superior to AmB-
d, nor are we aware of any situations in which these agents
would be contraindicated, with the exception of urinary tract
candidiasis, in which the protection of the kidney afforded by
the pharmacological properties of these formulations has the
theoretical potential to reduce delivery of AmB [22]. Animal
model studies suggest a pharmacokinetic and therapeutic ad-
vantage for L-AmB in the CNS [23]. Data demonstrating that
AmB-d–induced nephrotoxicity is associated with a 6.6-fold
increase in mortality have led many clinicians to use LFAmB
as initial therapy for individuals who are at high risk of ne-
phrotoxicity [24].
Triazoles
Fluconazole, itraconazole, voriconazole, and posaconazole
demonstrate similar activity against most Candida species [25,
26]. Each of the azoles has less activity against C. glabrata and
C. krusei. All of the azole antifungals inhibit cytochrome P450
enzymes to some degree. Thus, clinicians must carefully con-
sider the influence on a patient’s drug regimen when adding
or removing an azole. In large clinical trials, fluconazole dem-
onstrated efficacy comparable to that of AmB-d for the treat-
ment of candidemia [27, 28] and is also considered to be stan-
dard therapy for oropharyngeal, esophageal, and vaginal
candidiasis [29, 30]. Fluconazole is readily absorbed, with oral
bioavailability resulting in concentrations equal to ∼90% of
those achieved by intravenous administration. Absorption is
not affected by food consumption, gastric pH, or disease state.
Among the triazoles, fluconazole has the greatest penetration
into the CSF and vitreous body, achieving concentrations of at
least 50% of those in serum [31]; for this reason, it is used in
the treatment of CNS and intraocular Candida infections. Flu-
conazole achieves urine concentrations that are 10–20 times
the concentrations in serum. For patients with invasive can-
didiasis, fluconazole should be administered with a loading dose
of 800 mg (12 mg/kg), followed by a daily dose of 400 mg (6
mg/kg); a lower dosage is required in patients with creatinine
clearance !50 mL/min.
Itraconazole is generally reserved for patients with mucosal
candidiasis, especially those who have experienced treatment
failure with fluconazole [32]. There are few data that examine
the use of itraconazole in the treatment of invasive candidiasis.
Gastrointestinal absorption differs for the capsule and the oral
solution formulations. Histamine receptor antagonists and pro-
ton pump inhibitors result in decreased absorption of the cap-
sule formulation, whereas acidic beverages, such as carbonated
drinks and cranberry juice, enhance absorption [33]. Admin-
istration of the capsule formulation with food increases ab-
sorption, but the oral solution is better absorbed on an empty
stomach [34]. Oral formulations are dosed in adults at 200 mg
3 times daily for 3 days, then 200 mg once or twice daily
thereafter.
Voriconazole is effective for both mucosal and invasive can-
didiasis. Its clinical use has been primarily for step-down oral
therapy for patients with infection due to C. krusei and flu-
conazole-resistant, voriconazole-susceptible C. glabrata. CSF
and vitreous penetration is excellent [35, 36]. Voriconazole is
available in both oral and parenteral preparations. The oral
bioavailability of voriconazole is 190% and is not affected by
508
Table 2. Summary of recommendations for the treatment of candidiasis.
Condition or treatment group
Therapy
Primary Alternative Comments
Candidemia
Nonneutropenic adults Fluconazole 800-mg (12-mg/kg) load-
ing dose, then 400 mg (6 mg/kg)
daily or an echinocandina (A-I). For
species-specific recommendations,
see text.
LFAmB 3–5 mg/kg daily; or AmB-d
0.5–1 mg/kg daily; or voriconazole
400 mg (6 mg/kg) bid for 2 doses,
then 200 mg (3 mg/kg) bid (A-I)
Choose an echinocandin for moder-
ately severe to severe illness and
for patients with recent azole expo-
sure. Transition to fluconazole after
initial echinocandin is appropriate in
many cases. Remove all intravascu-
lar catheters, if possible. Treat 14
days after first negative blood cul-
ture result and resolution of signs
and symptoms associated with
candidemia. Ophthalmological ex-
amination recommended for all
patients.
Neutropenic patients An echinocandina or LFAmB 3–5 mg/
kg daily (A-II). For species-specific
recommendations, see text.
Fluconazole 800-mg (12-mg/kg) load-
ing dose, then 400 mg (6 mg/kg)
daily; or voriconazole 400 mg (6
mg/kg) bid for 2 doses then 200
mg (3 mg/kg ) bid (B-III)
An echinocandin or LFAmB is pre-
ferred for most patients. Flucona-
zole is recommended for patients
without recent azole exposure and
who are not critically ill. Voricona-
zole is recommended when addi-
tional coverage for molds is de-
sired. Intravascular catheter
removal is advised but is
controversial.
Suspected candidiasis
treated with empiric anti-
fungal therapy
Nonneutropenic patients Treat as above for candidemia. An
echinocandin or fluconazole is pre-
ferred (B-III).
LFAmB 3–5 mg/kg daily or AmB-d
0.5–1 mg/kg daily (B-III)
For patients with moderately severe
to severe illness and/or recent az-
ole exposure, an echinocandin is
preferred. The selection of appropri-
ate patients should be based on
clinical risk factors, serologic tests,
and culture data. Duration of ther-
apy is uncertain, but should be dis-
continued if cultures and/or serodi-
agnostic tests have negative
results.
Neutropenic patients LFAmB 3–5 mg/kg daily, caspofungin
70-mg loading dose, then 50 mg
daily (A-I), or voriconazole 400 mg
(6 mg/kg) bid for 2 doses then 200
mg (3 mg/kg) bid (B-I).
Fluconazole 800-mg (12-mg/kg) load-
ing dose, then 400 mg (6 mg/kg)
daily; or itraconazole 200 mg (3 mg/
kg) bid (B-I)
In most neutropenic patients, it is ap-
propriate to initiate empiric antifun-
gal therapy after 4 days of persis-
tent fever despite antibiotics.
Serodiagnostic tests and CT imag-
ing may be helpful. Do not use an
azole in patients with prior azole
prophylaxis.
Urinary tract infection
Asymptomatic cystitis Therapy not usually indicated, unless
patients are at high risk (e.g., neo-
nates and neutropenic adults) or
undergoing urologic procedures (A-
III)
… Elimination of predisposing factors
recommended. For high-risk pa-
tients, treat as for disseminated
candidiasis. For patients undergoing
urologic procedures, fluconazole,
200–400 mg (3–6 mg/kg) daily or
AmB-d 0.3–0.6 mg/kg daily for sev-
eral days before and after the
procedure.
Symptomatic cystitis Fluconazole 200 mg (3 mg/kg) daily
for 2 weeks (A-III)
AmB-d 0.3–0.6 mg/kg for 1–7 days;
or flucytosine 25 mg/kg qid for
7–10 days (B-III)
Alternative therapy as listed is recom-
mended for patients with flucona-
zole-resistant organisms. AmB-d
bladder irrigation is recommended
only for patients with refractory flu-
conazole-resistant organisms (e.g.,
Candida krusei and Candida
glabrata).
Pyelonephritis Fluconazole 200–400 mg (3–6 mg/kg)
daily for 2 weeks (B-III)
AmB-d 0.5–0.7 mg/kg daily with or
without 5-FC 25 mg/kg qid; or 5-FC
alone for 2 weeks (B-III)
For patients with pyelonephritis and
suspected disseminated candidia-
sis, treat as for candidemia.
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Table 2. (Continued.)
Condition or treatment group
Therapy
Primary Alternative Comments
Urinary fungus balls Surgical removal strongly recom-
mended (B-III); fluconazole 200–400
mg (3–6 mg/kg) daily; or AmB-d
0.5–0.7 mg/kg daily with or without
5-FC 25 mg/kg qid (B-III)
… Local irrigation with AmB-d may be a
useful adjunct to systemic antifun-
gal therapy.
Vulvovaginal candidiasis Topical agents or fluconazole 150 mg
single dose for uncomplicated vagi-
nitis (A-I)
… Recurrent vulvovaginal candidiasis is
managed with fluconazole 150 mg
weekly for 6 months after initial
control of the recurrent episode.
For complicated vulvovaginal candi-
diasis, see section VI.
Chronic disseminated
candidiasis
Fluconazole 400 mg (6 mg/kg) daily
for stable patients (A-III); LFAmB
3–5 mg/kg daily or AmB-d 0.5–0.7
mg/kg daily for severely ill patients
(A-III); after patient is stable,
change to fluconazole (B-III)
An echinocandina for several weeks
followed by fluconazole (B-III)
Transition from LFAmB or AmB-d to
fluconazole is favored after several
weeks in stable patients. Duration
of therapy is until lesions have re-
solved (usually months) and should
continue through periods of immu-
nosuppression (e.g., chemotherapy
and transplantation).
Candida osteoarticular
infection
Osteomyelitis Fluconazole 400 mg (6 mg/kg) daily
for 6–12 months or LFAmB 3–5
mg/kg daily for several weeks, then
fluconazole for 6–12 months (B-III)
An echinocandina or AmB-d 0.5–1
mg/kg daily for several weeks then
fluconazole for 6–12 months (B-III)
Duration of therapy usually is pro-
longed (6–12 months). Surgical de-
bridement is frequently necessary.
Septic arthritis Fluconazole 400 mg (6 mg/kg) daily
for at least 6 weeks or LFAmB 3–5
mg/kg daily for several weeks, then
fluconazole to completion (B-III)
An echinocandina or AmB-d 0.5–1
mg/kg daily for several weeks then
fluconazole to completion (B-III)
Duration of therapy usually is for at
least 6 weeks, but few data are
available. Surgical debridement is
recommended for all cases. For in-
fected prosthetic joints, removal is
recommended for most cases.
CNS candidiasis LFAmB 3–5 mg/kg with or without 5-
FC 25 mg/kg qid for several weeks,
followed by fluconazole 400–800
mg (6–12 mg/kg) daily (B-III)
Fluconazole 400–800 mg (6–12 mg/
kg) daily for patients unable to tol-
erate LFAmB
Treat until all signs and symptoms,
CSF abnormalities, and radiologic
abnormalities have resolved. Re-
moval of intraventricular devices is
recommended.
Candida endophthalmitis AmB-d 0.7–1 mg/kg with 5-FC 25 mg/
kg qid (A-III); or fluconazole 6–12
mg/kg daily (B-III); surgical interven-
tion for patients with severe endo-
phthalmitis or vitreitis (B-III)
LFAmB 3–5 mg/kg daily; voriconazole
6 mg/kg q12h for 2 doses, then
3–4 mg/kg q12h; or an
echinocandina (B-III)
Alternative therapy is recommended
for patients intolerant of or experi-
encing failure of AmB and 5-FC
therapy. Duration of therapy is at
least 4–6 weeks as determined by
repeated examinations to verify res-
olution. Diagnostic vitreal aspiration
should be done if etiology
unknown.
Candida infection of the car-
diovascular system
Endocarditis LFAmB 3–5 mg/kg with or without 5-
FC 25 mg/kg qid; or AmB-d 0.6–1
mg/kg daily with or without 5-FC
25 mg/kg qid; or an echinocandinb
(B-III)
Step-down therapy to fluconazole
400–800 mg (6–12 mg/kg) daily for
susceptible organism in stable pa-
tient with negative blood culture re-
sults (B-III)
Valve replacement is strongly recom-
mended. For those who are unable
to undergo surgical removal of the
valve, chronic suppression with flu-
conazole 400–800 mg (6–12 mg/kg)
daily is recommended. Lifelong
suppressive therapy for prosthetic
valve endocarditis if valve cannot
be replaced is recommended.
Pericarditis or myocarditis LFAmB 3–5 mg/kg daily; or flucona-
zole 400–800 mg (6–12 mg/kg)
daily; or an echinocandinb (B-III)
After stable, step-down therapy to flu-
conazole 400–800 mg (6–12 mg/kg)
daily (B-III)
Therapy is often for several months,
but few data are available. A peri-
cardial window or pericardiectomy
is recommended.
Suppurative
thrombophlebitis
LFAmB 3–5 mg/kg daily; or flucona-
zole 400–800 mg (6–12 mg/kg)
daily; or an echinocandinb (B-III)
After stable, step-down therapy to flu-
conazole 400–800 mg (6–12 mg/kg)
daily (B-III)
Surgical incision and drainage or re-
section of the vein is recom-
mended if feasible. Treat for at
least 2 weeks after candidemia has
cleared.
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Table 2. (Continued.)
Condition or treatment group
Therapy
Primary Alternative Comments
Infected pacemaker, ICD,
or VAD
LFAmB 3–5 mg/kg with or without 5-
FC 25 mg/kg qid; or AmB-d 0.6–1
mg/kg daily with or without 5-FC
25 mg/kg qid; or an echinocandinb
(B-III)
Step-down therapy to fluconazole
400–800 mg (6–12 mg/kg) daily for
susceptible organism in stable pa-
tient with negative blood culture re-
sults (B-III)
Removal of pacemakers and ICDs
strongly recommended. Treat for
4–6 weeks after the device re-
moved. For VAD that cannot be re-
moved, chronic suppressive ther-
apy with fluconazole is
recommended.
Neonatal candidiasis AmB-d 1 mg/kg daily (A-II); or flucona-
zole 12 mg/kg daily (B-II) for 3
weeks
LFAmB 3–5 mg/kg daily (B-III) A lumbar puncture and dilated retinal
examination should be performed
on all neonates with suspected in-
vasive candidiasis. Intravascular
catheter removal is strongly recom-
mended. Duration of therapy is at
least 3 weeks. LFAmB used only if
there is no renal involvement.
Echinocandins should be used with
caution when other agents cannot
be used.
Candida isolated from respi-
ratory secretions
Therapy not recommended (A-III) … Candida lower respiratory tract infec-
tion is rare and requires histopatho-
logic evidence to confirm a
diagnosis.
Nongenital mucocutaneous
candidiasis
Oropharyngeal Clotrimazole troches 10 mg 5 times
daily; nystatin suspension or pas-
tilles qid (B-II); or fluconazole
100–200 mg daily (A-I)
Itraconazole solution 200 mg daily; or
posaconazole 400 mg qd (A-II); or
voriconazole 200 mg bid; or AmB
oral suspension (B-II); IV
echinocandina or AmB-d 0.3 mg/kg
daily (B-II)
Fluconazole is recommended for
moderate-to-severe disease, and
topical therapy with clotrimazole or
nystatin is recommended for mild
disease. Treat uncomplicated dis-
ease for 7–14 days. For refractory
disease, itraconazole, voriconazole,
posaconazole, or AmB suspension
is recommended.
Esophageal Fluconazole 200–400 mg (3–6 mg/kg)
daily (A-I); an echinocandina; or
AmB-d 0.3–0.7 mg/kg daily (B-II)
Itraconazole oral solution 200 mg
daily; or posaconazole 400 mg bid;
or voriconazole 200 mg bid (A-III)
Oral fluconazole is preferred. For pa-
tients unable to tolerate an oral
agent, IV fluconazole, an echinocan-
din, or AmB-d is appropriate. Treat
for 14–21 days. For patients with
refractory disease, the alternative
therapy as listed or AmB-d or an
echinocandin is recommended,
NOTE. AmB, amphotericin B; AmB-d, amphotericin B deoxycholate; bid, twice daily; ICD, implantable cardiac defibrillator; IV, intravenous; LFAmB, lipid
formulation of amphotericin B; qid, 4 times daily; VAD, ventricular assist device; 5-FC, flucytosine.
a Echinocandin dosing in adults is as follows: anidulafungin, 200-mg loading dose, then 100 mg/day; caspofungin, 70-mg loading dose, then 50 mg/day;
and micafungin, 100 mg/day.
b For patients with endocarditis and other cardiovascular infections, higher daily doses of an echinocandin may be appropriate (e.g., caspofungin 50–150
mg/day, micafungin 100–150 mg/day, or anidulafungin 100–200 mg/day).
gastric pH, but it decreases when the drug is administered with
food [37]. In adults, the recommended oral dosing regimen
includes a loading dose of 400 mg twice daily, followed by 200
mg twice daily. Intravenous voriconazole is complexed to a
cyclodextrin molecule; after 2 loading doses of 6 mg/kg every
12 h, a maintenance dosage of 3–4 mg/kg every 12 h is rec-
ommended. Because of the potential for cyclodextrin accu-
mulation among patients with significant renal dysfunction,
intravenous voriconazole is not recommended for patients with
a creatinine clearance !50 mL/min [38]. Oral voriconazole does
not require dosage adjustment for renal insufficiency, but it is
the only triazole that requires dosage reduction for patients
with mild-to-moderate hepatic impairment. Common poly-
morphisms in the gene encoding the primary metabolic enzyme
for voriconazole result in wide variability of serum levels [39,
40]. Drug-drug interactions are common with voriconazole and
should be considered when initiating and discontinuing treat-
ment with this compound.
Posaconazole does not have an indication for primary can-
didiasis therapy. It demonstrates in vitro activity against Can-
dida species that is similar to that of voriconazole, but clinical
data are inadequate to make an evidence-based recommen-
dation for treatment of candidiasis other than oropharyngeal
candidiasis. Posaconazole is currently available only as an oral
suspension with high oral bioavailability, especially when given
with fatty foods [41], but absorption is saturated at relatively
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modest dosage levels. Thus, despite a prolonged elimination
half-life (124 h), the drug must be administered multiple times
daily (e.g., 200 mg 4 times daily or 400 mg twice daily). Similar
to itraconazole capsules, posaconazole absorption is optimal in
an acidic gastric environment.
Echinocandins
Caspofungin, anidulafungin, and micafungin are available only
as parenteral preparations [42–44]. The MICs of the echino-
candins are low for a broad spectrum of Candida species, in-
cluding C. glabrata and C. krusei. C. parapsilosis demonstrates
less in vitro susceptibility to the echinocandins than do most
other Candida species, which raises the concern that C. par-
apsilosis may be less responsive to the echinocandins. However,
in several clinical trials, this has not been demonstrated [45,
46]. Each of these agents has been studied for the treatment
of esophageal candidiasis [47–50] and invasive candidiasis [51–
54] in noncomparative and comparative clinical trials, and each
has been shown to be effective in these clinical situations. All
echinocandins have few adverse effects. The pharmacologic
properties in adults are also very similar and are each admin-
istered once daily intravenously [42–44]; the major route of
elimination is nonenzymatic degradation. None of the echin-
ocandins require dosage adjustment for renal insufficiency or
dialysis. Both caspofungin and micafungin undergo minimal
hepatic metabolism, but neither drug is a major substrate for
cytochrome P450. Caspofungin is the only echinocandin for
which dosage reduction is recommended for patients with
moderate to severe hepatic dysfunction.
Based on existing data, intravenous dosing regimens for in-
vasive candidiasis with the 3 compounds are as follows: cas-
pofungin, loading dose of 70 mg and 50 mg daily thereafter;
anidulafungin, loading dose of 200 mg and 100 mg daily there-
after; and micafungin, 100 mg daily.
Flucytosine
Flucytosine demonstrates broad antifungal activity against most
Candida species, with the exception of C. krusei. The compound
is available only as an oral formulation. The drug has a short
half-life (2.4–4.8 h) and is ordinarily administered at a dosage
of 25 mg/kg 4 times daily for patients with normal renal func-
tion. Flucytosine demonstrates excellent absorption after oral
administration (80%–90%), and most of the drug (190%) is
excreted unchanged in the urine [55]. Thus, dose adjustment
is necessary for patients with renal dysfunction [56].
Flucytosine is rarely administered as a single agent but is
usually given in combination with AmB for patients with in-
vasive diseases, such as Candida endocarditis or meningitis.
Occasionally, it is used for the treatment of urinary tract can-
didiasis due to susceptible organisms.
Pediatric Dosing
The pharmacokinetics of antifungal agents vary between adult
and pediatric patients, but the data on dosing for antifungal
agents in pediatric patients are limited. The pharmacological
properties of antifungal agents in children and infants have
been reviewed in detail [57, 58]. AmB-d kinetics are similar in
neonates and adults [59]. There are few data describing the use
of LFAmB in neonates and children. A phase I/II study of ABLC
(2–5 mg/kg per day) in the treatment of hepatosplenic can-
didiasis in children found that the area under the curve and
the maximal concentration of drug were similar to those in
adults [17]. There are anecdotal data reporting successful use
of L-AmB in neonates [60].
Flucytosine clearance is directly proportional to glomerular
filtration rate, and infants with a very low birth weight may
accumulate high plasma concentrations because of poor renal
function due to immaturity [61]. Thus, the use of flucytosine
without careful monitoring of serum drug levels is discouraged
in this group of patients.
The pharmacokinetics of fluconazole vary significantly with
age [62–64]. Fluconazole is rapidly cleared in children (plasma
half-life, ∼14 h). To achieve comparable drug exposure, the
daily fluconazole dose needs to be doubled, from 6 to 12 mg/
kg daily, for children of all ages and neonates [62]. In com-
parison with the volume of distribution (0.7 L/kg) and half-
life (30 h) seen in adults, neonates may have a higher volume
of distribution and longer half-life [63, 64]; it has been recently
reported that the volume of distribution in young infants and
neonates is 1 L/kg and that the half-life is 30–50 h [65]. These
data indicate that once-daily dosing of 12 mg/kg in premature
and term neonates will provide exposure similar to that in
adults who receive 400 mg daily. If the young infant’s creatinine
level is 11.2 mg/dL for 13 consecutive doses, the dosing interval
for 12 mg/kg may be increased to once every 48 h until the
serum creatinine level is !1.2 mg/dL.
When administered to infants and children, the oral solution
of itraconazole (5 mg/kg per day) provides potentially thera-
peutic concentrations in plasma [66]. Levels in children 6
months to 2 years of age are substantially lower than those
attained in adult patients; thus, children usually need twice-
daily dosing. A recent study of itraconazole solution in HIV-
infected children documented its efficacy for treating oro-
pharyngeal candidiasis in pediatric patients [67].
Voriconazole kinetics vary significantly between children and
adults [68], demonstrating linear elimination in children after
doses of 3 mg/kg and 4 mg/kg every 12 h. Thus, children up
to ∼12 years of age require higher doses of voriconazole than
do adults to attain similar serum concentrations. A dosage of
7 mg/kg every 12 h is currently recommended to achieve plasma
exposures comparable to those in an adult receiving 4 mg/kg
given every 12 h.
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Table 3. General patterns of susceptibility of Candida species.
Species Fluconazole Itraconazole Voriconazole Posaconazole Flucytosine Amphotericin B Candins
Candida albicans S S S S S S S
Candida tropicalis S S S S S S S
Candida parapsilosis S S S S S S S to Ra
Candida glabrata S-DD to R S-DD to R S-DD to R S-DD to R S S to I S
Candida krusei R S-DD to R S S I to R S to I S
Candida lusitaniae S S S S S S to R S
NOTE. I, intermediately susceptible; R, resistant; S, susceptible; S-DD: susceptible dose-dependent.
a Echinocandin resistance among C. parapsilosis isolates is uncommon.
There is growing experience with the echinocandins in chil-
dren and neonates [45, 69–72]. A recent study of caspofungin
in pediatric patients demonstrated the importance of dosing
based on body surface area rather than weight. With use of the
weight-based approach to pediatric dosing, 1 mg/kg resulted
in sub-optimal plasma concentrations for caspofungin, whereas
dosing based on 50 mg/m2 yielded plasma concentrations that
were similar to those in adults who were given a standard 50-
mg dose of caspofungin. Micafungin has been studied in chil-
dren and neonates; children should be treated with 2–4 mg/kg
daily, but neonates may require as much as 10–12 mg/kg daily
to achieve therapeutic concentrations [73]. Anidulafungin has
been studied in children 2–17 years of age and should be dosed
at 1.5 mg/kg/day [72]. Data for each of the echinocandins
suggest safety and efficacy in the pediatric population.
Considerations during Pregnancy
Systemic AmB is the treatment of choice for invasive candidiasis
in pregnant women [74]. Most azoles, including fluconazole,
itraconazole, and posaconazole, should generally be avoided in
pregnant women because of the possibility of birth defects as-
sociated with their use (category C). There are fewer data con-
cerning the echinocandins, but these should be used with cau-
tion during pregnancy (category C). Flucytosine and
voriconazole are contraindicated during pregnancy because of
fetal abnormalities observed in animals (category D) [74].
Therapeutic Drug Monitoring
Therapeutic drug monitoring for itraconazole and voriconazole
may be useful for patients receiving prolonged courses (e.g.,
4 weeks in duration) for deep-seated or refractory candidiasis.
Blood concentrations vary widely in patients receiving itracon-
azole. Serum concentrations are ∼30% higher when the solu-
tion is used than they are when the capsule is used, but wide
intersubject variability exists. Itraconazole concentrations in se-
rum should be determined only after steady state has been
reached, which takes ∼2 weeks. Serum levels should be obtained
to ensure adequate absorption, to monitor changes in the dos-
age of itraconazole or the addition of interacting medications,
and to assess adherence. Because of its long half-life, serum
concentrations of itraconazole vary little over a 24-h period,
and blood can be collected at any time in relation to drug
administration. When measured by high-pressure liquid chro-
matography, both itraconazole and its bioactive hydroxy-itra-
conazole metabolite are reported, the sum of which should be
considered in assessing drug levels.
Because of nonlinear pharmacokinetics in adults and genetic
differences in metabolism, there is both intrapatient and in-
terpatient variability in serum voriconazole concentrations.
Therapeutic drug monitoring should be considered for patients
receiving voriconazole, because drug toxicity has been observed
at higher serum concentrations, and reduced clinical response
has been observed at lower concentrations [39, 75].
Antifungal Susceptibility Testing
Intensive efforts to develop standardized, reproducible, and
clinically relevant susceptibility testing methods for fungi have
resulted in the development of the Clinical and Laboratory
Standards Institute M27-A3 methodology for susceptibility test-
ing of yeasts [76]. Data-driven interpretive breakpoints deter-
mined with use of this method are available for testing the
susceptibility of Candida species to fluconazole, itraconazole,
voriconazole, flucytosine, and the echinocandins [25, 76]. Al-
though the susceptibility of Candida to the currently available
antifungal agents is generally predictable if the species of the
infecting isolate is known, individual isolates do not necessarily
follow this general pattern (table 3) [25, 76]. For this reason,
susceptibility testing is increasingly used to guide the manage-
ment of candidiasis, especially in situations in which there is
a failure to respond to initial antifungal therapy. Expert opinion
suggests that laboratories perform routine antifungal suscep-
tibility testing against fluconazole for C. glabrata isolates from
blood and sterile sites and for other Candida species that have
failed to respond to antifungal therapy or in which azole re-
sistance is strongly suspected. Currently, antifungal resistance
in C. albicans is uncommon, and routine testing for antifungal
susceptibility against this species is not generally recommended.
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Non–Culture-Based Diagnostic Techniques
Several new diagnostic techniques offer promise for the early
diagnosis of invasive candidiasis. Several of these assays are
approved as adjuncts to the diagnosis of invasive candidiasis,
but their role in clinical practice is poorly defined. Several other
assays are under development but are not yet approved (see
below).
RECOMMENDATIONS FOR THE MANAGEMENT
OF CANDIDIASES
I. WHAT IS THE TREATMENT OF CANDIDEMIA
IN NONNEUTROPENIC PATIENTS?
Recommendations
1. Fluconazole (loading dose of 800 mg [12 mg/kg], then
400 mg [6 mg/kg] daily) or an echinocandin (caspofungin:
loading dose of 70 mg, then 50 mg daily; micafungin: 100 mg
daily; anidulafungin: loading dose of 200 mg, then 100 mg
daily) is recommended as initial therapy for most adult patients
(A-I). The Expert Panel favors an echinocandin for patients
with moderately severe to severe illness or patients who have
had recent azole exposure (A-III). Fluconazole is recommended
for patients who are less critically ill and who have no recent
azole exposure (A-III). The same therapeutic approach is ad-
vised for children, with attention to differences in dosing reg-
imens (B-III).
2. Transition from an echinocandin to fluconazole is rec-
ommended for patients who have isolates that are likely to be
susceptible to fluconazole (e.g., C. albicans) and who are clin-
ically stable (A-II).
3. For infection due to C. glabrata, an echinocandin is pre-
ferred (B-III). Transition to fluconazole or voriconazole is not
recommended without confirmation of isolate susceptibility (B-
III). For patients who initially received fluconazole or voricon-
azole, are clinically improved, and whose follow-up culture
results are negative, continuing an azole to completion of ther-
apy is reasonable (B-III).
4. For infection due to C. parapsilosis, fluconazole is rec-
ommended (B-III). For patients who have initially received an
echinocandin, are clinically improved, and whose follow-up
culture results are negative, continuing use of an echinocandin
is reasonable (B-III).
5. AmB-d (0.5–1.0 mg/kg daily) or LFAmB (3–5 mg/kg
daily) are alternatives if there is intolerance to or limited avail-
ability of other antifungal agents (A-I). Transition from AmB-
d or LFAmB to fluconazole therapy is recommended for pa-
tients who have isolates that are likely to be susceptible to
fluconazole (e.g., C. albicans) and who are clinically stable (A-
I).
6. Voriconazole (400 mg [6 mg/kg] twice daily for 2 doses,
then 200 mg [3 mg/kg] twice daily) is effective for candidemia
(A-I), but it offers little advantage over fluconazole and is rec-
ommended as step-down oral therapy for selected cases of can-
didiasis due to C. krusei or voriconazole-susceptible C. glabrata
(B-III).
7. Recommended duration of therapy for candidemia with-
out obvious metastatic complications is for 2 weeks after doc-
umented clearance of Candida species from the bloodstream
and resolution of symptoms attributable to candidemia (A-III).
8. Intravenous catheter removal is strongly recommended
for nonneutropenic patients with candidemia (A-II).
Evidence Summary
The selection of any particular agent for the treatment of can-
didemia should optimally take into account any history of re-
cent azole exposure, a history of intolerance to an antifungal
agent, the dominant Candida species and current susceptibility
data in a particular clinical unit or location, severity of illness,
relevant comorbidities, and evidence of involvement of the
CNS, cardiac valves, and/or visceral organs. Early initiation of
effective antifungal therapy is critical in the successful treatment
of candidemia, as demonstrated by recent data suggesting
higher mortality rates among patients with candidemia whose
therapy was delayed [77, 78].
Fluconazole remains standard therapy for selected patients
with candidemia, on the basis of abundant data from well-
designed clinical trials [27, 28, 53, 79]. There is little role for
itraconazole in this setting, given similar antifungal spectrum,
ease of administration, superior pharmacokinetics, and better
tolerability of fluconazole. Fluconazole should be considered
first-line therapy for patients who have mild to moderate illness
(i.e., are hemodynamically stable), who have no previous ex-
posure to azoles, and who do not belong in a group at high
risk of C. glabrata (infection e.g., elderly patients, patients with
cancer, and patients with diabetes). Patients with candidemia
and suspected concomitant endocardial or CNS involvement
should probably not receive fluconazole as initial therapy;
rather, they should receive an agent that is fungicidal, such as
AmB (for endocardial or CNS candidiasis) or an echinocandin
(for endocardial candidiasis). On the basis of data from recent
clinical trials [28, 51, 52, 54, 79], step-down therapy to flu-
conazole is reasonable for patients who have improved clinically
after initial therapy with an echinocandin or AmB and who
are infected with an organism that is likely to be susceptible
to fluconazole (e.g., C. albicans, C. parapsilosis, and Candida
tropicalis).
The echinocandins demonstrate significant fungicidal activ-
ity against all Candida species, and each has demonstrated suc-
cess in ∼75% of patients in randomized clinical trials. Because
of their efficacy, favorable safety profile, and very few drug
interactions, the echinocandins are favored for initial therapy
for patients who have a recent history of exposure to an azole,
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moderately severe to severe illness (i.e., are hemodynamically
unstable), allergy or intolerance to azoles or AmB, or high risk
of infection with C. krusei or C. glabrata. A short course of
intravenous echinocandin therapy (3–5 days) followed by tran-
sition to oral fluconazole or voriconazole (for C. krusei infec-
tion) is a reasonable approach to the treatment of candidemia
in the stable patient, but there are few clinical data to support
this management strategy. The Expert Panel favors fluconazole
over the 3 available echinocandins for treatment of candidemia
due to C. parapsilosis on the basis of the decreased in vitro
activity of echinocandins against C. parapsilosis [45, 46] and
reports of echinocandin resistance among selected isolates [80].
Most experts agree that the echinocandins are sufficiently sim-
ilar to be considered interchangeable.
Data from a recent randomized study suggest that an echin-
ocandin may be superior to fluconazole as primary therapy for
candidemia [53]. Although many experts agree that an echin-
ocandin is favored as initial therapy for patients with moder-
ately severe to severe disease due to invasive candidiasis, few
agree that an echinocandin is favored for all episodes, and it
is reasonable to consider the history of recent azole exposure,
severity of illness, and the likelihood of fluconazole resistance
in making a choice for initial antifungal therapy.
Voriconazole was shown to be as effective as AmB induction
therapy for 4–7 days, followed by fluconazole for candidemia
and invasive candidiasis [79]. Voriconazole possesses activity
against most Candida species, including C. krusei [26, 81], but
the need for more-frequent administration, less predictable
pharmacokinetics, more drug interactions, and poor tolerance
to the drug, compared with other systemic antifungals, make
it a less attractive choice for initial therapy. Voriconazole does
not provide predictable activity against fluconazole-resistant C.
glabrata [26, 81]. It does, however, fill an important niche for
patients who have fluconazole-resistant isolates of C. krusei, C.
guilliermondii, or C. glabrata that have documented voricon-
azole susceptibility and who are ready for transition from an
echinocandin or AmB to oral therapy.
Posaconazole has excellent in vitro activity against most Can-
dida species, but there are few clinical data to support its use
among patients with candidemia. On the basis of available data
and the lack of an intravenous formulation, it is difficult to
envision a significant role for posaconazole in the treatment of
candidemia, other than in select patients for whom transition
to an expanded-spectrum azole is warranted.
AmB-d is recommended as initial therapy when alternative
therapy is unavailable or unaffordable, when there is a history
of intolerance to echinocandins or azoles, when the infection
is refractory to other therapy, when the organism is resistant
to other agents, or when there is a suspicion of infection due
to non-Candida yeast, such as Cryptococcus neoformans. L-AmB
at doses of 3 mg/kg daily has been shown to be effective for
treatment of candidemia, based on a recent prospective clinical
trial [52]. Similarly, ABLC administered at 3 mg/kg/day has
been successfully used for the treatment of candidemia (E. J.
Anaissie, unpublished data). Infections due to Candida luis-
taniae are uncommon; for this organism, the Expert Panel fa-
vors the use of fluconazole or an echinocandin over AmB be-
cause of the observation of in vitro polyene resistance.
For all patients with candidemia, a dilated funduscopic ex-
amination sometime within the first week after initiation of
therapy and routine blood cultures to document clearance of
Candida from the bloodstream is strongly advised (see Perfor-
mance Measures). If there are no metastatic complications, the
duration of antifungal therapy is 14 days after resolution of
signs and symptoms attributable to infection and clearance of
Candida species from the bloodstream. This recommendation
is based on the results of several prospective, randomized trials
in which this rule has been successfully applied, and it is gen-
erally associated with few complications and relapses [27, 28,
51–54, 79]. The recommended length of therapy pertains to
all systemic antifungal therapy and includes sequential therapy
with AmB or an echinocandin followed by an azole.
Central venous catheters should be removed when candi-
demia is documented, if at all possible [82–84]. The data sup-
porting this are strongest among nonneutropenic patients and
show that catheter removal is associated with shorter duration
of candidemia [82, 83] and reduced mortality in adults [82,
84] and neonates [85]. Recently completed trials in adults sug-
gest better outcomes and shorter duration of candidemia
among patients in whom central venous catheters were re-
moved or replaced [28, 54]. Among neutropenic patients, the
role of the gastrointestinal tract as a source for disseminated
candidiasis is evident from autopsy studies, but in an individual
patient, it is difficult to determine the relative contributions of
the gastrointestinal tract versus catheter as primary sources of
candidemia [82, 86]. An exception is made for candidemia due
to C. parapsilosis, which is very frequently associated with cath-
eters [87]. There are no randomized studies on this topic, but
the Expert Panel strongly favors catheter removal when feasible.
The role for antifungal lock solutions is not well defined.
II. WHAT IS THE TREATMENT OF CANDIDEMIA
IN NEUTROPENIC PATIENTS?
Recommendations
9. An echinocandin (caspofungin, loading dose of 70 mg,
then 50 mg daily; micafungin, 100 mg daily (A-II); anidula-
fungin, loading dose of 200 mg, then 100 mg daily (A-III)) or
LFAmB (3–5 mg/kg daily) (A-II) is recommended for most
patients.
10. For patients who are less critically ill and who have no
recent azole exposure, fluconazole (800 mg [12 mg/kg] loading
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dose, then 400 mg [6 mg/kg] daily) is a reasonable alternative
(B-III). Voriconazole (400 mg [6 mg/kg] twice daily for 2 doses,
then 200 mg [3 mg/kg] twice daily) can be used in situations
in which additional mold coverage is desired (B-III).
11. For infections due to C. glabrata, an echinocandin is
preferred (B-III); LFAmB is an effective but less attractive al-
ternative because of cost and the potential for toxicity (B-III).
For patients who were already receiving voriconazole or flu-
conazole, are clinically improved, and whose follow-up culture
results are negative, continuing use of the azole to completion
of therapy is reasonable (B-III).
12. For infections due to C. parapsilosis, fluconazole or
LFAmB is preferred as initial therapy (B-III). If the patient is
receiving an echinocandin and is clinically stable and if follow-
up culture results are negative, continuing use of the echino-
candin until completion of therapy is reasonable. For infections
due to C. krusei, an echinocandin, LFAmB, or voriconazole is
recommended (B-III).
13. Recommended duration of therapy for candidemia
without persistent fungemia or metastatic complications is 2
weeks after documented clearance of Candida from the blood-
stream and resolution of symptoms attributable to candidemia
and resolution of neutropenia (A-III).
14. Intravenous catheter removal should be considered (B-
III).
Evidence Summary
Candidemia in neutropenic patients is a life-threatening infec-
tion that is associated with acute disseminated candidiasis, a
sepsis-like syndrome, multiorgan failure, and death. Candi-
demia associated with C. tropicalis is particularly virulent in
neutropenic hosts. Chronic disseminated candidiasis can ensue
as a complication of candidemia in neutropenic patients despite
antifungal therapy.
There are no adequately powered randomized controlled tri-
als of treatment of candidemia in neutropenic patients. The
data are largely derived from single-arm studies or from small
subsets of randomized controlled studies that have enrolled
mostly nonneutropenic patients. Historically, candidemia in the
neutropenic patient has been treated with an AmB formulation.
The availability of voriconazole and the echinocandins have led
to greater use of these agents in this clinical scenario but without
compelling clinical data. The extensive use of fluconazole for
prophylaxis to prevent invasive candidiasis in neutropenic pa-
tients and the lack of significant prospective data has led to a
diminished therapeutic role for this agent among these patients.
The numbers of neutropenic patients included in recent can-
didemia treatment studies are small, but response rates are
encouraging. In these trials, 50% of caspofungin recipients ver-
sus 40% of AmB-d recipients [51], 68% of micafungin recip-
ients versus 61% of L-AmB recipients [52], and 69% of mi-
cafungin recipients versus 64% of caspofungin recipients [54]
with neutropenia at onset of therapy were successfully treated.
Data from the recent randomized controlled trial of anidula-
fungin versus fluconazole enrolled too few neutropenic patients
with candidemia to generate meaningful data regarding efficacy
[53]. In 2 retrospective studies, successful outcomes for primary
treatment of neutropenic patients were reported in 64% of
those receiving AmB-d, 64% of those receiving fluconazole,
and 68% of those receiving caspofungin [88, 89].
An extremely important factor influencing the outcome of
candidemia in neutropenic patients is the recovery of neutro-
phils during therapy. In a large retrospective cohort of 476
patients with cancer who had candidemia, persistent neutro-
penia was associated with a greater chance of treatment failure
[87].
Additional insights can be gleaned from data derived from
studies of empirical antifungal therapy involving febrile patients
with neutropenia who had candidemia at baseline. In these
studies, baseline candidemia was cleared in 73% of those treated
with AmB-d versus 82% of those treated with L-AmB [90] and
in 67% of those treated with caspofungin versus 50% of those
treated with L-AmB [91]. Data from a large randomized trial
also suggest that voriconazole is a reasonable choice for febrile
patients with neutropenia and suspected invasive candidiasis
for whom additional mold coverage is desired [92].
On the basis of these limited data, the success rates of an-
tifungal therapy for candidemia in patients with neutropenia
do not appear to be substantially different from those reported
in the large randomized trials of nonneutropenic patients.
Moreover, these data do not suggest less favorable outcomes
associated with fluconazole and voriconazole, but many phy-
sicians prefer LFAmB or an echinocandin, which may be more
fungicidal, as first-line agents. Similar to the approach in non-
neutropenic patients, the recommended duration of therapy
for candidemia in neutropenic patients is for 14 days after
resolution of attributable signs and symptoms and clearance of
the bloodstream of Candida species, provided that there has
been recovery from neutropenia. This recommendation is based
on the limited data from prospective randomized trials and has
been associated with few complications and relapses [51, 52,
54].
The management of intravascular catheters in neutropenic
patients with candidemia is less straightforward than in their
nonneutropenic counterparts. Distinguishing gut-associated
from vascular catheter–associated candidemia can be difficult
in these patients [86], the data for catheter removal is less
compelling, and the consequences of catheter removal often
create significant intravenous access problems. Nonetheless, the
Expert Panel suggests consideration of venous catheter removal
(including removal of tunneled catheters) for neutropenic pa-
tients who have persistent candidemia and in whom it is lo-
gistically feasible.
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III. WHAT IS THE EMPIRICAL TREATMENT FOR
SUSPECTED INVASIVE CANDIDIASIS IN
NONNEUTROPENIC PATIENTS?
Recommendations
15. Empirical therapy for suspected candidiasis in non-
neutropenic patients is similar to that for proven candidiasis.
Fluconazole (800-mg [12-mg/kg] loading dose, then 400 mg
[6 mg/kg] daily), caspofungin (70-mg loading dose, then 50
mg daily), anidulafungin (200-mg loading dose, then 100 mg
daily), or micafungin (100 mg daily) is recommended as initial
therapy (B-III). An echinocandin is preferred for patients with
recent azole exposure, patients with moderately severe to severe
illness, or patients who are at high risk of infection due to C.
glabrata or C. krusei (B-III).
16. AmB-d (0.5–1.0 mg/kg daily) or LFAmB (3–5 mg/kg
daily) are alternatives if there is intolerance to other antifungals
or limited availability of other antifungals (B-III).
17. Empirical antifungal therapy should be considered in
critically ill patients with risk factors for invasive candidiasis
and no other known cause of fever and should be based on
clinical assessment of risk factors, serologic markers for invasive
candidiasis, and/or culture data from nonsterile sites (B-III).
Evidence Summary
Candida species are an increasing cause of sepsis among non-
neutropenic patients receiving intensive care; one-half to two-
thirds of all episodes of candidemia occur in an ICU or surgical
ward [5, 8]. Identification of patients at risk of Candida infec-
tions and prompt initiation of antifungal therapy are critical
[77, 78]. Candida colonization, severity of illness, number of
broad-spectrum antibiotic agents used and duration of use,
previous surgery (especially bowel surgery), receipt of dialysis,
use of central venous catheters, receipt of parenteral nutrition,
and length of ICU stay are important risk factors for invasive
candidiasis [93–98]. The level of Candida colonization has a
low positive predictive value, and routine assessment of colo-
nization is labor intensive and expensive [93, 99]. Signs and
symptoms of candidiasis are nonspecific, and microbiology and
imaging techniques lack sensitivity and specificity.
Early diagnosis of invasive candidiasis remains a challenge;
thus, clinical prediction rules have been developed to identify
patients in the ICU who are at high risk of candidiasis [100–
102]. Characterized by high specificity but a low sensitivity,
these rules allow the identification of only a small proportion
of ICU patients who will develop candidiasis. Newer serological
diagnostic tests have become available to assist in the assessment
of patients with suspected candidiasis. Combined measurement
of mannan and anti-mannan antibodies has yielded encour-
aging results and is worthy of additional evaluation [103]. De-
tection of b-D-glucan has shown good overall performance
characteristics, with a sensitivity of 80%–90% in patients with
candidemia [104, 105], confirming previous results obtained
in patients with hematological malignancies [106]. Real-time
PCR is a nonvalidated but intriguing methodology that holds
promise as an early diagnostic aid for candidemia [107]. These
encouraging data offer new perspectives for early diagnosis of
Candida infections, but continued evolution of these assays will
be required before they can be used routinely.
Few clinical studies have carefully examined the impact of
empirical or preemptive treatment strategies. In one study, pre-
emptive therapy with fluconazole in selected colonized patients
in a surgical ICU was associated with reduced incidence of
proven candidiasis [108], and in another study, early preemp-
tive fluconazole therapy in patients who had had gastrointes-
tinal surgery for bowel obstruction or perforation had some
impact on the resolution of fever, the incidence of candidemia,
the length of ICU stay, and mortality [109]. In a more recent
study of ICU patients at risk of invasive candidiasis and with
unexplained fever, empiric fluconazole (800 mg daily for 14
days) was not associated with better outcomes, compared with
placebo [110].
Criteria for starting empirical antifungal therapy in nonneu-
tropenic patients remain poorly defined. Early initiation of an-
tifungal therapy may reduce morbidity, mortality, and length
of stay in critically ill patients, but the widespread use of these
agents must be balanced against the risk of toxicity, costs, and
the emergence of resistance. Empirical antifungal therapy
should be considered in critically ill patients with risk factors
for invasive candidiasis and no other known cause of fever.
Preference should be given to an echinocandin in hemodyn-
amically unstable patients, in patients previously exposed to an
azole, and in those known to be colonized with azole-resistant
Candida species. LFAmB and AmB-d are alternatives to an
echinocandin, but the risk of toxicity is a concern. Empirical
therapy with fluconazole may be considered in non–critically
ill patients who are known to be colonized with azole-suscep-
tible Candida species or who have no prior exposure to azoles.
IV. WHAT IS THE EMPIRICAL TREATMENT FOR
SUSPECTED INVASIVE CANDIDIASIS IN
NEUTROPENIC PATIENTS?
Refer to the 2002 IDSA guidelines for the use of antimicrobial
agents in neutropenic patients with cancer [111].
Recommendations
18. LFAmB (3–5 mg/kg daily), caspofungin (70-mg loading
dose, then 50 mg daily) (A-I), or voriconazole (6 mg/kg twice
daily for 2 doses, then 3 mg/kg twice daily) are recommended
(B-I).
19. Fluconazole (800-mg [12-mg/kg] loading dose, then
400 mg [6 mg/kg] daily) and itraconazole (200 mg [3mg/kg]
twice daily) are alternative agents (B-I).
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20. AmB-d is an effective alternative, but there is a higher
risk of toxicity than there is with LFAmB (A-I).
21. Azoles should not be used for empirical therapy in
patients who have received an azole for prophylaxis (B-II).
Evidence Summary
Empirical antifungal therapy in persistently febrile and neutro-
penic patients with hematological malignancies, allogeneic he-
matopoietic stem cell transplantation, and other underlying
conditions became a standard of care in the late 1980s when
it became clear that the lack of sensitivity of microbiological
and clinical findings resulted in delayed diagnosis. AmB-d in
neutropenic patients with persistent, unexplained fever despite
4–7 days of broad-spectrum antibiotics was shown to reduce
the occurrence of invasive fungal infections and related mor-
tality in 2 randomized, prospective clinical trials [112, 113].
Although these studies provided the scientific basis for empir-
ical antifungal therapy, they were statistically underpowered.
Since that time, several clinical trials have compared the efficacy
and safety of various antifungal agents for this indication. In
a majority of studies, the overall response was assessed by a
composite end point consisting of a combination of resolution
of fever during neutropenia, successful treatment of baseline
fungal infections, absence of breakthrough fungal infection,
discontinuation of therapy because of drug-related lack of ef-
ficacy or toxicity, and survival.
In recent years, imaging techniques, such as chest CT, and
serial measurements of fungal antigens have become integral
to the evaluation of the neutropenic patient with persistent,
unexplained fever despite broad-spectrum antibacterial therapy
[114, 115]. Serial measurements of Aspergillus galactomannan,
mannan and anti-mannan antibodies, or b-D-glucan have been
shown to be useful additions to culture methods [105, 116–
118]. Combined serum galactomannan screening, chest CT, and
bronchoalveolar lavage can enhance the diagnosis of invasive
fungal infections and reduce the use of empirical therapy in
neutropenic patients [119].
Empirical therapy in persistently febrile and neutropenic pa-
tients should cover infections caused by yeasts and molds.
Given its toxicity, AmB-d is no longer a treatment of first choice
unless other safer agents are unavailable. L-AmB is as efficacious
as AmB-d and is associated with fewer breakthrough fungal
infections and less infusion-related toxicity and nephrotoxicity
[90]. ABCD and ABLC are efficacious but associated with a
higher incidence of infusion-related toxicity than L-AmB [120,
121].
Fluconazole is less toxic, but its usefulness is limited by its
relatively narrow spectrum [122–124]. Itraconazole has been
shown to be as efficacious as AmB-d and less toxic [125]; it is
available only as an oral formulation and has variable oral
bioavailability and frequent gastrointestinal adverse effects. Vor-
iconazole has been shown to prevent breakthrough fungal in-
fections and is effective for aspergillosis and candidemia [79,
92]. Posaconazole has been shown to be effective prophylaxis
against invasive fungal infections in high-risk neutropenic pa-
tients and allogeneic hematopoietic stem cell transplant recip-
ients [126, 127], but its role as empirical therapy has not been
determined. Azoles are unsuitable for empirical therapy if they
have been used for prior prophylaxis.
Among the echinocandins, caspofungin has been shown to
be as effective as and better tolerated than L-AmB for empirical
therapy [91]. Micafungin has been shown to prevent fungal
infections in hematopoietic stem cell transplant recipients [42,
128], but micafungin and anidulafungin have not been studied
as empirical therapy for neutropenic patients.
V. WHAT IS THE TREATMENT FOR URINARY
TRACT INFECTIONS DUE TO CANDIDA
SPECIES?
Recommendations: asymptomatic candiduria
22. Treatment is not recommended unless the patient be-
longs to a group at high risk of dissemination (A-III). Elimi-
nation of predisposing factors often results in resolution of
candiduria (A-III).
23. High-risk patients include neutropenic patients, infants
with low birth weight, and patients who will undergo urologic
manipulations. Neutropenic patients and neonates should be
managed as described for invasive candidiasis. For those pa-
tients undergoing urologic procedures, fluconazole adminis-
tered at a dosage of 200- 400 mg (3–6 mg/kg) daily or AmB-
d administered at a dosage of 0.3–0.6 mg/kg daily for several
days before and after the procedure is recommended (B-III).
24. Imaging of the kidneys and collecting system to exclude
abscess, fungus ball, or urologic abnormality is prudent when
treating asymptomatic patients with predisposing factors (B-
III).
Recommendations: symptomatic candiduria
25. For candiduria with suspected disseminated candidia-
sis, treatment as described for candidemia is recommended (A-
III).
26. For cystitis due to a fluconazole-susceptible Candida
species, oral fluconazole at a dosage of 200 mg (3 mg/kg) daily
for 2 weeks is recommended (A-III). For fluconazole-resistant
organisms, AmB-d at a dosage of 0.3–0.6 mg/kg daily for 1–7
days or oral flucytosine at a dosage of 25 mg/kg 4 times daily
for 7–10 days are alternatives (B-III). AmB-d bladder irrigation
is generally not recommended but may be useful for treatment
of patients with fluconazole-resistant Candida species, espe-
cially C. glabrata (B-III).
27. For pyelonephritis due to fluconazole-susceptible or-
ganisms, oral fluconazole at a dosage of 200–400 mg (3–6 mg/
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kg) daily for 2 weeks is recommended (B-III). For patients with
fluconazole-resistant Candida strains, especially C. glabrata, al-
ternatives include AmB-d at a dosage of 0.5–0.7 mg/kg daily
with or without flucytosine at a dosage of 25 mg/kg 4 times
daily (B-III), or flucytosine alone at a dosage of 25 mg/kg 4
times daily (B-III) for 2 weeks.
28. For fungus balls, surgical intervention is strongly rec-
ommended in nonneonates (B-III). Fluconazole at a dosage of
200–400 mg (3–6 mg/kg) daily is recommended (B-III). AmB-
d at a dosage of 0.5–0.7 mg/kg daily with or without flucytosine
at a dosage of 25 mg/kg 4 times daily is an alternative (B-III).
If access to the renal collecting system is available, an adjunct
to systemic therapy is irrigation with AmB-d at a concentration
of 50 mg/L of sterile water (B-III). Treatment duration should
be until symptoms have resolved and urine cultures no longer
yield Candida species (B-III).
Evidence Summary
The presence of yeast in the urine, whether microscopically
visualized or grown in culture, must be evaluated in the context
of the particular clinical setting to determine its relevance and
the need for antifungal therapy. If no predisposing condition
is uncovered in an asymptomatic patient, only observation is
warranted [129, 130]. Among patients with predisposing con-
ditions, management of that condition alone, such as removal
of an indwelling catheter, may be sufficient to eliminate can-
diduria without specific antifungal therapy. Several conditions
require an aggressive approach to persistent candiduria, even
among asymptomatic patients. These include neonates with low
birth weight and severely immunocompromised patients with
fever and candiduria, in whom disseminated candidiasis should
be considered. For Candida cystitis, fluconazole is the drug of
first choice. It is highly water-soluble, primarily excreted in
urine in its active form, and easily achieves urine levels ex-
ceeding the MIC for most Candida strains. No other currently
available azole is useful, because of minimal excretion of active
drug into urine. For patients who have cystitis and who are
allergic to fluconazole or who clearly experience treatment fail-
ure despite maximum doses and optimal management of urol-
ogic abnormalities, treatment with oral flucytosine, systemic
AmB-d, and bladder irrigation with AmB-d are alternatives.
Flucytosine demonstrates good activity against most Candida
isolates and is concentrated in urine. Treatment with flucytosine
is limited by toxicity and the development of resistance when
flucytosine is used alone; it is not recommended as primary
therapy for patients with uncomplicated Candida cystitis.
Irrigation of the bladder with a suspension of AmB-d resolves
candiduria in 190% of patients [131], but there is a high relapse
rate. This approach is generally discouraged except as a measure
to treat refractory cystitis due to azole-resistant organisms, such
as C. glabrata and C. krusei.
For most patients with Candida pyelonephritis, fluconazole
is the drug of choice. However, C. glabrata accounts for ∼20%
of urine isolates obtained from adults [132, 133], and such
infections frequently require treatment with AmB-d. LFAmB
should not be considered as a first choice because of presumed
low concentrations of the drug in renal tissue. Failure of LFAmB
therapy has been described in the treatment of Candida pyelo-
nephritis in experimental animals and patients [22, 134].
There are several animal studies and a report describing a
small number of patients in which echinocandins were used
successfully for the treatment of renal parenchymal infections
[135, 136]. Although there are clinical circumstances, such as
renal insufficiency and/or the isolation of fluconazole-resistant
organisms, in which an echinocandin or voriconazole may be
considered for the treatment of Candida pyelonephritis, the
Expert Panel does not currently recommend these agents be-
cause of very limited clinical data and poor urinary
concentrations.
Candida prostatitis and epididymo-orchitis are rare [137–
139]. Most patients will require surgical drainage of abscesses
or other surgical debridement, as well as antifungal therapy.
Fluconazole is the agent of choice, but treatment recommen-
dations are based on anecdotal data.
Fungus balls can occur anywhere in the urinary collecting
system. Aggressive surgical debridement is central to successful
treatment in most nonneonatal cases. Systemic treatment with
AmB-d (with or without flucytosine) or fluconazole has been
used most often [140, 141]. If a percutaneous device provides
direct access to the renal pelvis, ureters, or bladder, local irri-
gation with AmB-d at a dosage of 50 mg/L of sterile water
should be considered as an adjunct to systemic antifungal ther-
apy, but the optimal dose and duration of AmB-d irrigation
have not been defined [141]. Other methods to facilitate the
breakdown and passage of fungus balls include intermittent
saline irrigation, debulking of the fungal mass through a per-
cutaneous device, and irrigation with streptokinase [142–144].
VI. WHAT IS THE TREATMENT FOR
VULVOVAGINAL CANDIDIASIS (VVC)?
Recommendations
29. Several topical antifungal agents are effective therapy
for VVC, and no agent is clearly superior (table 4) (A-I).
30. A single 150-mg dose of fluconazole is recommended
for the treatment of uncomplicated Candida VVC (A-I).
31. For recurring Candida VVC, 10–14 days of induction
therapy with a topical or oral azole, followed by fluconazole at
a dosage of 150 mg once per week for 6 months, is recom-
mended (A-I).
Evidence Summary
VVC is usually caused by C. albicans but can be caused by
other Candida species. A diagnosis of Candida VVC can usually
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Table 4. Intravaginal agents.
Butoconazole 2% cream 5 g intravaginally for 3 days OR
Butoconazole 2% cream 5 g (butoconazole1-sustained release),
single intravaginal application OR
Clotrimazole 1% cream 5 g intravaginally for 7–14 days OR
Clotrimazole 100-mg vaginal tablet for 7 days OR
Clotrimazole 100-mg vaginal tablet, 2 tablets for 3 days OR
Miconazole 2% cream 5 g intravaginally for 7 days OR
Miconazole 100-mg vaginal suppository, 1 suppository for 7 days
OR
Miconazole 200-mg vaginal suppository, 1 suppository for 3 days
OR
Miconazole 1200-mg vaginal suppository, 1 suppository for 1 day
OR
Nystatin 100,000-unit vaginal tablet, 1 tablet for 14 days OR
Tioconazole 6.5% ointment 5 g intravaginally in a single applica-
tion OR
Terconazole 0.4% cream 5 g intravaginally for 7 days OR
Terconazole 0.4% cream 5 g intravaginally for 3 days OR
Terconazole 80-mg vaginal suppository, 1 suppository for 3 days
be made clinically when a woman complains of pruritus, ir-
ritation, vaginal soreness, external dysuria, and dyspareunia of-
ten accompanied by a change in vaginal discharge. Signs include
vulvar edema, erythema, excoriation, fissures, and a white,
thick, curd-like vaginal discharge. Unfortunately, these symp-
toms and signs are nonspecific and can be the result of a variety
of infectious and noninfectious etiologies. Before proceeding
with empirical antifungal therapy, diagnosis should be con-
firmed by a wet mount preparation with use of saline and 10%
potassium hydroxide to demonstrate the presence of yeast or
hyphae. In addition, VVC is associated with normal pH (!4.5).
For those with negative wet mount findings, vaginal cultures
for Candida should be obtained.
VVC can be classified as either uncomplicated (as in ∼90%
of cases) or complicated (∼10% of cases) on the basis of clinical
presentation, microbiological findings, host factors, and re-
sponse to therapy [145]. Complicated VVC is defined as severe
or recurrent disease, infection due to Candida species other
than C. albicans, and/or VVC in an abnormal host [145]. A
variety of topical and systemic or oral agents are available. No
evidence exists to show the superiority of any topical agent
formulation or regimen [146, 147]. Similarly, oral and topical
antimycotics achieve entirely equivalent results [148]. Uncom-
plicated VVC can be effectively treated with either single-dose
or short-course therapy, both of which achieve 190% response.
Complicated VVC requires topical therapy administered intra-
vaginally daily for ∼7 days or multiple doses of fluconazole
(150 mg every 72 h for 3 doses) [147]. Therapy with an azole,
including voriconazole, is frequently unsuccessful for C. gla-
brata VVC. Topical boric acid, administered in a gelatin capsule
at a dosage of 600 mg daily for 14 days, may be successful
[149]. Other alternatives include topical 17% flucytosine cream
alone or in combination with 3% AmB cream administered
daily for 14 days; these agents must be compounded by a phar-
macy. Azole-resistant C. albicans infections are extremely rare
[150].
Recurrent VVC is defined as 4 episodes of symptomatic
VVC within 1 year and is usually caused by azole-susceptible
C. albicans [151]. After control of contributing factors, such as
diabetes, induction therapy with 10–14 days of a topical or oral
azole should be followed by a suppressive regimen for at least
6 months. The most convenient and well-tolerated regimen is
once weekly oral fluconazole at a dose of 150 mg, which
achieves control of symptoms in 190% of patients [151]. After
cessation of maintenance therapy, a 40%–50% recurrence rate
can be anticipated. If fluconazole therapy is not feasible, topical
clotrimazole (200 mg twice weekly) or clotrimazole (500-mg
vaginal suppository once weekly) or other intermittent topical
azole treatments are advised. Treatment of VVC should not
differ on the basis of HIV infection status; identical response
rates are anticipated for HIV-positive and HIV-negative
women.
VII. WHAT IS THE TREATMENT FOR CHRONIC
DISSEMINATED CANDIDIASIS?
Recommendations
32. Fluconazole at a dosage of 400 mg (6 mg/kg) daily is
recommended for clinically stable patients (A-III). LFAmB at
a dosage of 3–5 mg/kg daily or AmB-d at a dosage of 0.5–0.7
mg/kg daily can be used to treat acutely ill patients or patients
with refractory disease (A-III). Induction therapy with AmB
for 1–2 weeks, followed by oral fluconazole at a dosage of 400
mg (6 mg/kg) daily, is also recommended (B-III).
33. Anidulafungin (loading dose of 200 mg, then 100 mg
daily), micafungin (100 mg daily), or caspofungin (loading dose
of 70 mg, then 50 mg daily for 1–2 weeks) are alternatives for
initial therapy, followed by oral fluconazole when clinically ap-
propriate (B-III).
34. Therapy should be continued for weeks to months,
until calcification occurs or lesions resolve (A-III). Premature
discontinuation of antifungal therapy can lead to recurrent
infection.
35. Patients with chronic disseminated candidiasis who re-
quire ongoing chemotherapy or undergo stem cell transplan-
tation should continue to receive antifungal therapy throughout
the period of high risk to prevent relapse (A-III).
Evidence Summary
Approaches to this syndrome, also termed hepatosplenic can-
didiasis, are based on anecdotal case reports and open-label
series. The bulk of the data and clinical experience are with
AmB-d [152, 153], LFAmB [154], and fluconazole [155, 156].
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Some experts feel it helpful to begin treatment with AmB for
1–2 weeks, followed by fluconazole therapy for as long as several
months. Caspofungin [157], micafungin [54], and voriconazole
[158] have also been used successfully in small numbers of
cases. Receipt of therapy for several months and until lesions
have either calcified or cleared radiographically is essential to
prevent relapse. Additional chemotherapy and stem cell trans-
plantation can proceed when clinically appropriate, provided
that antifungal therapy is continued. A novel approach recently
put forward is to consider this syndrome, which almost always
appears during recovery from neutropenia, to be a form of
immune reconstitution inflammatory syndrome and to use cor-
ticosteroids in conjunction with antifungal agents for treatment
[159]. Additional studies will be required in order to establish
the benefit of this approach.
VIII. WHAT IS THE TREATMENT FOR
OSTEOARTICULAR CANDIDA INFECTIONS?
Recommendations
36. For osteomyelitis, the Expert Panel recommends flu-
conazole at a dosage of 400 mg (6 mg/kg) daily for 6–12 months
or LFAmB at a dosage of 3–5 mg/kg daily for at least 2 weeks,
followed by fluconazole at a dosage of 400 mg daily for 6–12
months (B-III). Alternatives include an echinocandin or AmB-
d at a dosage of 0.5–1 mg/kg daily for at least 2 weeks, followed
by fluconazole at a dosage of 400 mg daily for 6–12 months
(B-III). Surgical debridement in selected cases is advised (B-
III).
37. For septic arthritis, the Expert Panel recommends treat-
ment for at least 6 weeks with fluconazole at a dosage of 400
mg (6 mg/kg) daily or LFAmB at a dosage of 3–5 mg/kg daily
for at least 2 weeks, followed by fluconazole at a dosage of 400
mg daily (B-III). Alternatives include an echinocandin or AmB-
d at a dosage of 0.5–1 mg/kg daily for at least 2 weeks, followed
by fluconazole at a dosage of 400 mg daily for the remainder
of therapy (B-III). Surgical debridement is indicated in all cases
(A-III).
38. For infection involving a prosthetic device, device re-
moval is recommended for most cases (A-III). Therapy for at
least 6 weeks with the above dosages of fluconazole, LFAmB,
an echinocandin, or AmB-d is recommended (B-III). If the
device cannot be removed, chronic suppression with flucona-
zole is recommended (B-III).
Evidence Summary
Approaches to osteoarticular infections are based on anecdotal
case reports and open-label series. The published experience is
heavily dominated by reports of use of AmB-d, fluconazole,
and more recently, caspofungin. Use of LFAmB, other azoles,
and other echinocandins would appear to be reasonable, but
experience is limited.
Candida osteomyelitis appears to be best treated with surgical
debridement of the affected area in conjunction with antifungal
therapy. Some authors have shown that surgical therapy is im-
portant for vertebral osteomyelitis [160, 161], but this is not
a commonly held view. AmB-d at a dosage of 0.5–1 mg/kg
daily for 6–10 weeks has been used successfully [161]. Flucon-
azole has been used successfully as initial therapy for patients
who have susceptible isolates, although treatment failures have
also been reported [162–165]. There are reports of the use of
itraconazole [166] and caspofungin [167]. The addition of
AmB-d to bone cement appears to be safe and may be of value
in complicated cases [168]. The data suggest that surgical de-
bridement and an initial course of AmB for 2–3 weeks, followed
by treatment with fluconazole for a total duration of therapy
of 6–12 months, would also be rational.
On the basis of a small number of cases, Candida medias-
tinitis and sternal osteomyelitis in patients who have undergone
sternotomy can be treated successfully with surgical debride-
ment followed by either AmB or fluconazole [163, 169]. Irri-
gation of the mediastinal space with AmB-d is not recom-
mended, because it can cause irritation. Antifungal therapy of
several months’ duration, similar to that needed for osteo-
myelitis at other sites, appears to be appropriate.
Adequate drainage is critical to successful therapy of Candida
arthritis. In particular, management of Candida arthritis of the
hip requires open drainage. Case reports have documented
cures with AmB, fluconazole, and caspofungin therapy in com-
bination with adequate drainage [170–172]. Administration of
either AmB or fluconazole produces substantial synovial fluid
levels, so that intra-articular therapy is not necessary. Therapy
for at least 6 weeks is required in most cases.
Candida prosthetic joint infection generally requires resec-
tion arthroplasty, although success with medical therapy alone
has been described [173, 174]. Antifungal therapy mirrors that
for native joint infection. A new prosthesis may be inserted
after documentation of clearance of the infection, typically
weeks or months after prosthetic joint removal. If the prosthetic
device cannot be removed, then chronic suppression with an
antifungal, usually fluconazole, is necessary.
IX. WHAT IS THE TREATMENT FOR CNS
CANDIDIASIS IN ADULTS?
Recommendations
39. LFAmB at a dosage of 3–5 mg/kg daily, with or without
flucytosine at a dosage of 25 mg/kg 4 times daily, is recom-
mended for the initial several weeks of treatment (B-III).
40. Fluconazole at a dosage of 400–800 mg (6–12 mg/kg)
daily is recommended as step-down therapy after the patient
responds to initial treatment with LFAmB and flucytosine.
Therapy should continue until all signs and symptoms, CSF
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abnormalities, and radiologic abnormalities have resolved (B-
III).
41. Removal of infected ventricular devices is recom-
mended (A-III).
Evidence Summary
CNS Candida infections in adults can occur as a manifestation
of disseminated candidiasis, as a complication of a neurosur-
gical procedure (especially after CSF shunt placement), or as
an isolated chronic infection [175–181]. Meningitis is the most
common presentation, but multiple small abscesses throughout
the brain parenchyma, large solitary brain abscesses, and epi-
dural abscesses have been reported [182–184]. Most cases are
due to C. albicans, with very few reports of C. glabrata and
other species causing infection [176, 178, 179, 181, 183].
No randomized controlled trials have been performed to
evaluate the most appropriate treatment. Single cases and small
series are reported, and most experience has accrued with the
use of AmB-d, with or without flucytosine [175, 176, 178–181].
The Expert Panel favors LFAmB because of the decreased risk
of nephrotoxicity. L-AmB attained higher levels in the brain
than did ABLC and AmB-d in a rabbit model of Candida
meningoencephalitis [23], and there is some clinical experience
with use of this formulation for Candida meningitis in neonates
[185]. The combination of AmB and flucytosine is appealing
because of the in vitro synergism noted with the combination
and the excellent CSF concentrations achieved by flucytosine
[181]. The length of therapy with AmB alone or in combination
with flucytosine has not been defined, but the Expert Panel
favors several weeks of therapy before transition to treatment
with an azole (after the patient has shown clinical and CSF
improvement).
Fluconazole achieves excellent levels in CSF and brain tissue
and has proved useful for treatment of Candida CNS infections
as step-down therapy after AmB and flucytosine [175–177].
Fluconazole has been used successfully as sole therapy [175,
176, 179, 186], but treatment failures also have been noted,
and it is not favored by the Expert Panel as primary therapy
[175, 176, 179, 187]. On the basis of these limited data, the
Expert Panel recommends that fluconazole as initial therapy
be reserved for those patients for whom LFAmB is contrain-
dicated. Fluconazole combined with flucytosine has been re-
ported to cure Candida meningitis in a few patients [178, 188].
There are no reports of the use of voriconazole or posacon-
azole for CNS candidiasis. Voriconazole achieves excellent levels
in CSF [36], but posaconazole CSF levels are low [189]. For
the rare case of C. glabrata or C. krusei meningitis, voriconazole
seems to be appropriate therapy after initial treatment with
AmB and flucytosine.
Echinocandins have been used infrequently for CNS can-
didiasis. There are case reports of both treatment failure and
success [184, 190], and there are reports of CNS breakthrough
infections after therapy for candidemia. These agents cannot
be recommended for CNS candidiasis.
Removal of an infected ventricular device without the ad-
ministration of an antifungal agent has proved curative in some
patients [176, 177, 179]. However, most physicians combine
device removal with systemic antifungal therapy or use both
systemic and intraventricular AmB-d injected into the device
before its removal [175, 179].
X. WHAT IS THE TREATMENT FOR CANDIDA
ENDOPHTHALMITIS?
Recommendations
42. AmB-d at a dosage of 0.7–1 mg/kg daily, combined
with flucytosine at a dosage of 25 mg/kg administered 4 times
daily, is recommended for advancing lesions or lesions threat-
ening the macula (A-III). Fluconazole at a dosage of 400–800
mg daily (loading dose of 12 mg/kg then 6–12 mg/kg daily) is
an acceptable alternative for less severe endophthalmitis (B-
III). LFAmB at a dosage of 3–5 mg/kg daily, voriconazole at a
dosage of 6 mg/kg twice daily for 2 doses and 3–4 mg/kg twice
daily thereafter, or an echinocandin can be used to treat patients
who are intolerant of or experiencing treatment failure with
AmB-d in combination with flucytosine or fluconazole (B-III).
43. The recommended duration of therapy is at least 4–6
weeks and is determined by the stabilization or resolution of
lesions as documented by repeated ophthalmological exami-
nations (A-III).
44. All patients with candidemia should have at least 1
dilated retinal examination early in the course of therapy, pref-
erably performed by an ophthalmologist (A-II). It is especially
important to examine patients who cannot communicate re-
garding visual disturbances.
45. A diagnostic vitreal aspirate is recommended for pa-
tients with endophthalmitis of unknown origin (A-III). The
Expert Panel strongly recommends ophthalmologic consulta-
tion for consideration of partial vitrectomy and intravitreal
antifungal therapy with AmB-d for all patients with severe en-
dophthalmitis and vitreitis (B-III).
Evidence Summary
There are no prospective studies for the treatment of Candida
endophthalmitis. The majority of published cases report the
use of intravenous and/or intravitreal AmB-d with or without
oral flucytosine as initial therapy [191–195]. Oral or intrave-
nous fluconazole has also been used successfully as initial, sal-
vage, and transition therapy [195, 196]. Although the data are
very limited, LFAmB, the echinocandins, and voriconazole are
reasonable options for treatment of patients who are not re-
sponding to conventional therapy with AmB-d or fluconazole
[197–200]. However, caution is advised with use of the echin-
ocandins because of their poor ocular penetration. Voriconazole
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at a dosage of 3–4 mg/kg twice daily appears to be safe and
achieves excellent intravitreal levels [35]; it can also be given
topically [201]. Among the newer antifungal agents, the pub-
lished experience is greatest with voriconazole [35, 197, 200,
201].
Early surgical intervention with a partial vitrectomy is an
important adjunct to antifungal therapy in more-advanced
cases and can be a sight-saving procedure [195]. The value of
intraocular instillation of antifungals at the time of vitrectomy,
in addition to standard systemic and topical therapy, has not
been well studied, but it is commonly practiced. The optimal
duration of antifungal therapy has not been determined, but
most experts advise at least 4–6 weeks of systemic treatment
and continuation of treatment until all clinical evidence of
intraocular infection has resolved.
The definitive diagnosis of Candida endophthalmitis still
rests on the isolation of the organism from the vitreous body
by culture methods or histopathological identification of the
organism. There are few data on the value of non–culture-
based methodology, such as PCR, in this condition [202].
XI. WHAT IS THE TREATMENT FOR CANDIDA
INFECTIONS OF THE CARDIOVASCULAR
SYSTEM?
Recommendations
46. For native valve endocarditis, LFAmB at a dosage of 3–
5 mg/kg daily with or without flucytosine at a dosage of 25
mg/kg 4 times daily is recommended (B-III). Alternatives in-
clude AmB-d at a dosage of 0.6–1 mg/kg daily with or without
flucytosine at a dosage of 25 mg/kg 4 times daily or an echin-
ocandin (higher dosages may be necessary than for treatment
of candidemia; e.g., caspofungin at a dosage of 50–150 mg daily,
micafungin at a dosage of 100–150 mg daily, or anidulafungin
at a dosage of 100–200 mg daily) (B-III). Step-down therapy
to fluconazole at a dosage of 400–800 mg (6–12 mg/kg) daily
should be considered among patients with susceptible Candida
isolates who have demonstrated clinical stability and clearance
of Candida from the bloodstream (B-III). Valve replacement is
recommended, and treatment should continue for at least 6
weeks after valve replacement and should continue for a longer
duration in patients with perivalvular abscesses and other com-
plications (B-III).
47. For patients who cannot undergo valve replacement,
long-term suppression with fluconazole at a dosage of 400–800
mg (6–12 mg/kg) daily is recommended (B-III).
48. For prosthetic valve endocarditis (PVE), the recom-
mendations above apply, and suppressive therapy should be
lifelong if valve replacement is not possible (B-III).
49. For pericarditis, LFAmB at a dosage of 3–5 mg/kg daily,
AmB-d at a dosage of 0.6–1 mg/kg daily, an echinocandin
administered at the dosages noted in recommendation 46, or
fluconazole at a dosage of 400–800 mg (6–12 mg/kg) daily for
as long as several months, in combination with either a peri-
cardial window or pericardiectomy, is recommended (B-III).
Step-down therapy to fluconazole at a dosage of 400–800 mg
(6–12 mg/kg) daily should be considered for patients who have
initially responded to AmB or an echinocandin and who are
clinically stable (B-III).
50. For myocarditis, treatment as for endocarditis (as out-
lined in recommendation 46) is recommended (B-III).
51. For suppurative thrombophlebitis, catheter removal
and incision and drainage or resection of the vein, if feasible,
is recommended (B-III). LFAmB at a dosage of 3–5 mg/kg daily,
AmB-d at a dosage of 0.6–1 mg/kg daily, fluconazole at a dosage
of 400–800 mg (6–12 mg/kg) daily, or an echinocandin at the
dosages noted in recommendation 46 for at least 2 weeks after
candidemia has cleared is recommended (B-III). Step-down
therapy to fluconazole at a dosage of 400–800 mg (6–12 mg/
kg) daily should be considered for patients who have initially
responded to AmB or an echinocandin and who are clinically
stable (B-III). Resolution of the thrombus can be used as evi-
dence to discontinue antifungal therapy if clinical and culture
data are supportive (B-III).
52. For pacemaker and implantable cardiac defibrillator
wire infections, removal of the entire device and systemic an-
tifungal therapy with LFAmB at a dosage of 3–5 mg/kg daily
with or without flucytosine at a dosage of 25 mg/kg 4 times
daily, AmB-d at a dosage of 0.6–1 mg/kg daily with or without
flucytosine at a dosage of 25 mg/kg 4 times daily, or an echin-
ocandin at the dosages noted in recommendation 46 is rec-
ommended (B-III). Step-down therapy to fluconazole at a dos-
age of 400–800 mg (6–12 mg/kg) daily should be considered
for patients with susceptible Candida isolates who have dem-
onstrated clinical stability and clearance of Candida from the
bloodstream (B-III). For infections limited to generators and/
or pockets, 4 weeks of antifungal therapy after removal of the
device is recommended (B-III). For pacemaker and implantable
cardiac defibrillator wire infections, at least 6 weeks of anti-
fungal therapy after wire removal is recommended (B-III).
53. For ventricular assist devices that cannot be removed,
treatment with LFAmB, AmB-d, or an echinocandin at the
dosages noted in recommendation 46 is recommended (B-III).
After candidemia has cleared and the patient has responded
clinically, fluconazole at a dosage of 400–800 mg (6–12 mg/kg)
daily is recommended as step-down therapy (B-III). Chronic
suppressive therapy with fluconazole is warranted until the de-
vice is removed (B-III).
Evidence Summary
Medical therapy of endocarditis has occasionally been curative
[203–211], but the optimum therapy for both native and pros-
thetic valve endocarditis in adults is a combination of valve
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replacement and a long course of antifungal therapy [212, 213].
This recommendation is based on anecdotal case reports, case
series, and clinical experience. Valve repair and vegetectomy
are alternatives to valve replacement. Most of the cases reported
in the literature have been treated with AmB-d with or without
flucytosine [205, 212–217]. Azoles, usually fluconazole, have
been used for completion of therapy. Because of less toxicity
and the ability to administer higher dosages, LFAmB are cur-
rently favored over AmB-d. A prospective, open-label clinical
trial and several case reports show a role for the echinocandins
in the treatment of endocarditis [209, 211, 218–224]. Caspo-
fungin at a dosage of 50–150 mg daily has been used success-
fully; data are limited for the other echinocandins. Higher-than-
usual dosages of the echinocandins may be necessary to treat
Candida endocarditis. Other cases have been reported of suc-
cessful treatment using caspofungin in combination with
LFAmB, fluconazole, or voriconazole [209, 221, 222].
In neonates, medical therapy alone, usually with AmB-d, has
been most frequently used [216, 217]. Success rates for the
treatment of neonatal Candida endocarditis are comparable for
those treated medically and those treated with combined med-
ical and surgical therapy [216]. Mural endocarditis, an entity
associated with a high failure rate, has been successfully treated
with caspofungin combined with voriconazole [222].
Lifelong suppressive therapy with fluconazole at a dosage of
400–800 mg daily has been successfully used after a course of
primary therapy in patients for whom cardiac surgery is judged
to be unacceptably risky and also has been advocated to prevent
late recurrence of Candida PVE [221, 225]. Because Candida
endocarditis has a propensity to relapse months to years later,
follow-up should be maintained for several years [214, 215].
Most experience in the treatment of pericarditis is with AmB-
d or fluconazole, as noted in case reports and small series [226,
227]. A few patients have been cured with only pericardiocen-
tesis and antifungal therapy [226], but the preferred procedures
are creation of a pericardial window or pericardiectomy. There
are few other data to guide therapy. Antifungal treatment
should continue for several months until resolution of signs
and symptoms of pericardial inflammation.
AmB-d or LFAmB, with or without flucytosine, and vori-
conazole have all been used successfully to treat myocarditis.
Treatment duration may need to be for as long as several
months if myocardial abscesses are present [228].
Although most experience treating suppurative thrombo-
phlebitis has been with AmB-d, the Expert Panel supports the
use of LFAmB because of decreased nephrotoxicity and the
need to treat for prolonged periods. Fluconazole therapy has
also been successful in some cases [229, 230]. Any of the agents
used for primary treatment of candidemia, including echino-
candins and voriconazole, should be effective [231]. Surgical
excision of the vein plays an important role in the treatment
of peripheral Candida thrombophlebitis. When a central vein
is involved, surgery is not usually an option. In some cases,
systemic anticoagulation or thrombolytic therapy has been used
as adjunctive therapy, but there are insufficient data to routinely
recommend their use.
There are a few case reports of Candida infections of trans-
venous pacemakers [232, 233] and implantable cardiac defib-
rillators [234, 235]. Combined surgical and medical therapy is
advocated [232, 234, 235]. Medical therapy alone has failed
[233]. There is a paucity of data on Candida infections of
ventricular assist devices, but the Expert Panel feels that sup-
pressive azole therapy after initial AmB or echinocandin therapy
is warranted until the device is removed.
XII. WHAT IS THE TREATMENT FOR NEONATAL
CANDIDIASIS?
Recommendations
54. AmB-d at a dosage of 1 mg/kg daily is recommended
for neonates with disseminated candidiasis (A-II). If urinary
tract involvement is excluded, LFAmB at a dosage of 3–5 mg/
kg daily can be used (B-II). Fluconazole at a dosage of 12 mg/
kg daily is a reasonable alternative (B-II). The recommended
length of therapy is 3 weeks (B-II).
55. A lumbar puncture and a dilated retinal examination
are recommended in neonates with sterile body fluid and/or
urine cultures positive for Candida species (B-III). Imaging of
the genitourinary tract, liver, and spleen should be performed
if sterile body fluid cultures have persistently positive results
(B-III).
56. Echinocandins should be used with caution and gen-
erally limited to situations in which resistance or toxicity pre-
clude the use of fluconazole or AmB-d (B-III).
57. Intravascular catheter removal is strongly recom-
mended (A-II).
58. In nurseries with high rates of invasive candidiasis, flu-
conazole prophylaxis may be considered in neonates with birth
weights !1000 g (A-I). Antifungal drug resistance, drug-related
toxicity, and neurodevelopmental outcomes should be observed
(A-III).
Evidence Summary
Neonatal candidiasis differs from invasive disease in older pa-
tients. Neonates present with subtle symptoms. The primary
risk factors are prematurity and day of life; younger and pre-
mature infants are more often infected. Dosing of antifungal
agents is substantially different for neonates than it is for older
children. Outcomes for neonates differ markedly from those
for older patients. Although mortality is lower (∼20%) in ne-
onates, these infants frequently have CNS disease [236]. CNS
involvement in the neonate usually manifests as meningoen-
cephalitis and should be assumed to be present in the neonate
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with candidemia because of the high incidence of this com-
plication. Neurologic impairment is common in survivors;
therefore, careful follow-up of neurodevelopmental parameters
is important.
Failure to promptly remove or replace central venous cath-
eters for infants with candidemia places the infant at increased
risk of prolonged infection, mortality, and long-term irrevers-
ible neurodevelopmental impairment [85, 236]. Removal or
replacement of the catheter at an anatomically distinct site
should be performed unless contraindicated.
Treatment of neonatal candidiasis with fluconazole and
AmB-d has been evaluated in small, single-center trials [237–
239] and in a multi-center cohort study [236]. Fluconazole and
AmB-d both appear to be acceptable choices for therapy. The
role of flucytosine in neonates with Candida meningitis is ques-
tionable and is not routinely recommended [181, 236].
Fluconazole prophylaxis at a dosage of 3 mg/kg or 6 mg/kg
twice weekly significantly reduces rates of invasive candidiasis
in premature neonates in nurseries that have a very high in-
cidence of Candida infections. In 2 recent studies, the incidence
of candidiasis in the placebo arms were 20% in neonates weigh-
ing !1000 g and 13% in neonates weighing 1000–1500 g [240,
241]. In contrast, most neonatal intensive care units have an
incidence of !5% in neonates who weigh !1000 g and ∼1%
in neonates who weigh 1000–1500 g. Almost 40% of neonatal
nurseries have an incidence that is 10-fold less (!2% in neonates
who weigh !1000 g) than that reported in the randomized
trials [236, 242, 243]. Pharmacokinetic and prospective safety
data are very limited for fluconazole in premature infants, and
systematic long-term neurologic follow-up data after routine
prophylaxis have not been reported. Because there are unknown
risks for neurologic and cognitive disorders after fluconazole
exposure in neonates, neurodevelopmental parameters should
be followed in neonates who receive this agent. The Expert
Panel recommends routine fluconazole prophylaxis for pre-
mature infants and infants with extremely low birth weights in
nurseries that have a high incidence of invasive candidiasis.
XIII. WHAT IS THE SIGNIFICANCE OF
CANDIDA ISOLATED FROM RESPIRATORY
SECRETIONS?
Recommendation
59. Growth of Candida from respiratory secretions rarely
indicates invasive candidiasis and should not be treated with
antifungal therapy (A-III)
Evidence Summary
Candida pneumonia and lung abscess are very uncommon
[244, 245]. Candida colonization of the bronchial tree in crit-
ically ill patents who receive mechanical ventilation is common,
but the lungs have innate defense mechanisms that render them
relatively resistant to tissue invasion by Candida species. Only
rarely after aspiration of oropharyngeal material does a primary
Candida pneumonia or abscess develop. More commonly, he-
matogenously disseminated candidiasis produces lesions in the
lung, as well as in other organs. Diagnosis of bona fide Candida
pneumonia requires histopathological confirmation.
In contrast to pneumonia, colonization of the airway with
Candida species and/or contamination of the respiratory se-
cretions with oropharyngeal material are extremely common.
Unfortunately, a positive culture from respiratory secretions is
frequently used as an indication to initiate antifungal therapy
in febrile patients who have no other evidence of invasive dis-
ease. Multiple prospective and retrospective studies, including
autopsy studies, consistently demonstrate the poor predictive
value of the growth of Candida from respiratory secretions,
including bronchoalveolar lavage fluid. Because of the rarity of
Candida pneumonia, the extremely common finding of Can-
dida in respiratory secretions, and the lack of specificity of this
finding [246–248], a decision to initiate antifungal therapy
should not be made on the basis of respiratory tract culture
results alone.
XIV. WHAT IS THE TREATMENT FOR
NONGENITAL MUCOCUTANEOUS
CANDIDIASIS?
Recommendations: oropharyngeal candidiasis
60. For mild disease, clotrimazole troches at a dosage of
10 mg 5 times daily, nystatin suspension at a concentration of
100,000 U/mL and a dosage of 4–6 mL 4 times daily, or 1–2
nystatin pastilles (200,000 U each) administered 4 times daily
for 7–14 days is recommended (B-II).
61. For moderate to severe disease, oral fluconazole at a
dosage of 100–200 mg (3 mg/kg) daily for 7–14 days is rec-
ommended (A-I).
62. For fluconazole-refractory disease, either itraconazole
solution at a dosage of 200 mg daily or posaconazole suspension
at a dosage of 400 mg twice daily for 3 days, then 400 mg daily
for up to 28 days, are recommended (A-II). Voriconazole at a
dosage of 200 mg twice daily or a 1-mL oral suspension of
AmB-d, administered at a dosage of 100 mg/mL 4 times daily,
are recommended when treatment with other agents has failed
(B-II). Intravenous echinocandin or AmB-d at a dosage of 0.3
mg/kg daily can be used in treating patients with refractory
disease (B-II).
63. Chronic suppressive therapy is usually unnecessary for
patients with HIV infection (A-I). If suppressive therapy is
required, fluconazole at a dosage of 100 mg 3 times weekly is
recommended (A-I). Treatment with HAART is recommended
to reduce recurrent infections (A-I).
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64. For denture-related candidiasis, disinfection of the den-
ture, in addition to antifungal therapy, is recommended (B-II).
Recommendations: esophageal candidiasis
65. Systemic antifungal therapy is always required (A-II).
Oral fluconazole at a dosage of 200–400 mg (3–6 mg/kg) daily
for 14–21 days is recommended (A-I). Intravenous fluconazole
at a dosage of 400 mg (6 mg/kg) daily, AmB-d at a dosage of
0.3–0.7 mg/kg daily, or an echinocandin should be used for
patients who cannot tolerate oral therapy (B-II). A diagnostic
trial of antifungal therapy is appropriate before performing an
endoscopic examination (B-II).
66. For fluconazole-refractory disease, itraconazole solu-
tion at a dosage of 200 mg daily, posaconazole suspension at
a dosage of 400 mg twice daily, or voriconazole at a dosage of
200 mg twice daily administered intravenously or orally for 14–
21 days is recommended (A-III). Micafungin at a dosage of
150 mg daily, caspofungin at a dosage of 50 mg daily, anidu-
lafungin at a dosage of 200 mg daily, or AmB-d at a dosage of
0.3–0.7 mg/kg daily are acceptable alternatives (B-II).
67. Suppressive therapy with fluconazole at a dosage of
100–200 mg 3 times weekly is recommended for recurrent in-
fections (A-I).
68. In patients with AIDS, treatment with HAART is rec-
ommended to reduce recurrent infections (A-I).
Evidence Summary
Most cases of oropharyngeal and esophageal candidiasis are
caused by C. albicans, either alone or in mixed infection [249,
250]. Symptomatic infections caused by C. glabrata and C.
krusei alone have been described [251]. Multiple randomized
prospective studies of oropharyngeal candidiasis have been per-
formed involving patients with AIDS and patients with cancer.
Most patients respond initially to topical therapy [249, 252,
253]. In HIV-infected patients, symptomatic relapses may occur
sooner with topical therapy than with fluconazole [252], and
resistance may develop with either regimen. Fluconazole and
itraconazole solution are superior to ketoconazole and itra-
conazole capsules [254–256]. A dosage of itraconazole solution
of 2.5 mg/kg twice daily has been recommended for pediatric
patients 5 years of age [67]. Local effects of oral solutions
may be as important as systemic effects. Posaconazole suspen-
sion is also as efficacious as fluconazole in patients with AIDS
[257].
Recurrent infections typically occur in patients with ongoing
immunosuppression, especially those who have AIDS. Long-
term suppressive therapy with fluconazole is effective in the
prevention of oropharyngeal candidiasis [30, 258, 259]. Long-
term suppressive therapy with fluconazole was compared with
the episodic use of fluconazole in response to symptomatic
disease. Continuous suppressive therapy reduced the relapse
rate more effectively than did intermittent therapy, but it was
associated with increased microbiological resistance. The fre-
quency of refractory disease was the same for the 2 groups [30].
Oral AmB-d, nystatin, and itraconazole capsules are less effec-
tive than fluconazole in preventing oropharyngeal candidiasis
[260, 261].
Fluconazole-refractory infections should be treated initially
with itraconazole solution. Between 64% and 80% of patients
will respond to this therapy [251, 262]. Posaconazole suspen-
sion is efficacious in ∼74% of patients with refractory oro-
pharyngeal or esophageal candidiasis [263], and voriconazole
may be efficacious for fluconazole-refractory infections [264].
Intravenous caspofungin, micafungin, or anidulafungin are rea-
sonable alternatives to the triazoles [47–50]. Oral or intrave-
nous AmB-d is also effective in some patients [265]. Immu-
nomodulation with adjunctive granulocyte-macrophage
colony-stimulating factor [266] and IFN-g [267] have been
used for refractory oral candidiasis.
The presence of oropharyngeal candidiasis and dysphagia or
odynophagia is predictive of esophageal candidiasis. A thera-
peutic trial with fluconazole for patients with presumed esoph-
ageal candidiasis is a cost-effective alternative to endoscopic
examination; most patients with esophageal candidiasis will
have resolution of their symptoms within 7 days after the start
of therapy [268]. Fluconazole is superior to ketoconazole, itra-
conazole capsules, and flucytosine; itraconazole solution is
comparable to fluconazole for the treatment of esophageal can-
didiasis [269, 270]. Up to 80% of patients with fluconazole-
refractory infections will respond to itraconazole solution [262].
Voriconazole is as efficacious as fluconazole and has shown
success in the treatment of cases of fluconazole-refractory dis-
ease, but it is associated with a higher rate of adverse events
[264, 271].
The echinocandins are associated with relapse rates that are
higher than those noted with fluconazole [47–50]. Fluconazole-
refractory disease responds to caspofungin, and it is likely that
micafungin and anidulafungin are similarly effective. In patients
with advanced AIDS, recurrent infections are common, and
long-term suppressive therapy with fluconazole is effective in
preventing recurrences [30].
In HIV-infected patients, the use of HAART has been as-
sociated with decreasing rates of oral carriage of C. albicans
and reduced frequency of symptomatic oropharyngeal candi-
diasis [272]. Thus, HAART should be used as adjunctive ther-
apy whenever possible for all HIV-infected patients with oro-
pharyngeal or esophageal candidiasis.
Chronic mucocutaneous candidiasis is a rare condition that
is characterized by chronic, persistent onychomycosis and mu-
cocutaneous lesions due to Candida species. Some patients have
a thymoma or autoimmune polyendocrinopathy syndrome
type 1 [273]. Fluconazole should be used as initial therapy for
candidiasis in these patients. Response to antifungal therapy
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may be delayed when there is extensive skin or nail involve-
ment, and relapses almost invariably occur. Thus, most patients
require chronic suppressive antifungal therapy. Development
of fluconazole-refractory infections is common [274]. Patients
with fluconazole-refractory Candida infections should be
treated similar to patients with AIDS who have fluconazole-
refractory infections.
XV. SHOULD ANTIFUNGAL PROPHYLAXIS BE
USED FOR SOLID-ORGAN TRANSPLANT
RECIPIENTS, ICU PATIENTS, NEUTROPENIC
PATIENTS RECEIVING CHEMOTHERAPY, AND
STEM CELL TRANSPLANT RECIPIENTS AT RISK
OF CANDIDIASIS?
Recommendations
69. For solid-organ transplant recipients, fluconazole at a
dosage of 200–400 mg (3–6 mg/kg) daily or LAmB at a dosage
of 1–2 mg/kg daily, each for at least 7–14 days, is recommended
as postoperative prophylaxis for high-risk liver (A-I), pancreas
(B-II), and small bowel (B-III) transplant recipients.
70. For ICU patients, fluconazole at a dosage of 400 mg
(6 mg/kg) daily is recommended for high-risk patients in adult
units with a high incidence of invasive candidiasis (B-I).
71. For patients with chemotherapy-induced neutropenia,
fluconazole at a dosage of 400 mg (6 mg/kg) daily (A-I), po-
saconazole at a dosage of 200 mg 3 times per day (A-I), or
caspofungin at a dosage of 50 mg daily (B-II) is recommended
during induction chemotherapy for the duration of neutro-
penia. Oral itraconazole at a dosage of 200 mg daily is an
effective alternative (A-I) but offers little advantage and is less
well tolerated than these agents.
72. For stem cell transplant recipients with neutropenia,
fluconazole at a dosage of 400 mg (6 mg/kg) daily, posaconazole
at a dosage of 200 mg 3 times daily, or micafungin at a dosage
of 50 mg daily is recommended during the period of risk of
neutropenia (A-I).
Evidence Summary
Patients who undergo liver transplantation who have at least
2 key risk factors, including retransplantation, creatinine level
12.0 mg/dL, choledochojejunostomy, intraoperative use of 140
U of blood products, prolonged intraoperative time (11 h), and
fungal colonization detected at least 2 days before and 3 days
after transplantation have been identified as being at high risk
of invasive candidiasis [275, 276]. One retrospective trial using
fluconazole [277] and several prospective trials using L-AmB
[278] or fluconazole [279, 280] showed reduced rates of in-
vasive fungal infection. The largest study compared fluconazole
with placebo, both given for 70 days after surgery, and showed
fungal infections in 6% of fluconazole recipients, compared
with 23% of placebo recipients [280]. The most recent study
of antifungal prophylaxis in high-risk liver transplant recipients
compared L-AmB administered at a dosage of 2 mg/kg/day
with placebo for 14 days after transplantation and demonstrated
a numerical benefit for L-AmB [281].
The risk of candidiasis among pancreas transplant recipients
is probably less than that among liver transplant recipients.
However, a retrospective review of 445 consecutive pancreas
transplant recipients revealed a 6% frequency of intra-abdom-
inal fungal infection in those who received fluconazole pro-
phylaxis at a dosage of 400 mg/day for 7 days after transplan-
tation, compared with a 10% frequency ( significant)Pp not
for those who did not receive prophylaxis [282]. There also
were significant improvements in 1-year graft survival rate and
overall survival among patients without infection. Small bowel
transplant recipients are a group at great risk of invasive fungal
infection [283]. There are no randomized trials of antifungal
prophylaxis among this small group of patients, but most ex-
perts agree that fluconazole at a dosage of 400 mg daily (6 mg/
kg daily in children) for at least 2 weeks after transplantation
is reasonable. The risk of invasive candidiasis after transplan-
tation of other solid organs, such as kidneys and hearts, appears
to be too low to warrant routine prophylaxis [284].
For ICUs that show very high rates of invasive candidiasis,
compared with the normal rates of 1%–2%, antifungal pro-
phylaxis may be warranted [285], and selected ICU patients
who are at highest risk (110%) of invasive candidiasis may
benefit from antifungal prophylaxis [102]. There are 3 ran-
domized, placebo-controlled trials that have shown a reduction
in the incidence of invasive candidiasis in single units or single
hospitals selecting patients at high risk of infection [286–288].
Recent meta-analyses have confirmed this finding; however, it
is important to stress that the primary studies and subsequent
analysis have all failed to show a survival benefit associated with
this strategy [289, 290]. None of the above studies of antifungal
prophylaxis in the ICU have demonstrated increased resistance
to fluconazole or major ecological shifts in Candida species.
In neutropenic chemotherapy recipients, a meta-analysis of
randomized, placebo-controlled trials has shown that system-
ically active antifungal agents can reduce the number of su-
perficial and invasive Candida infections [291]. A randomized
controlled trial showed that receipt of posaconazole decreased
invasive fungal infections, compared with receipt of fluconazole
or itraconazole in patients with chemotherapy-induced neu-
tropenia who had acute leukemia and myelodysplastic syn-
drome [127], and an open-label study of prophylaxis with cas-
pofungin versus itraconazole in patients with hematologic
malignancies undergoing induction chemotherapy found the 2
drugs to be equivalent [292]. A meta-analysis of 13 randomized
controlled trials demonstrated the efficacy of itraconazole (ad-
ministered orally and intravenously) as antifungal prophylaxis
in neutropenic patients with hematologic malignacies, but itra-
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conazole offers little advantage over many other antifungal
agents and is less well tolerated [293].
In stem cell transplant recipients, micafungin administered
at a dosage of 50 mg daily before engraftment significantly
reduced episodes of candidiasis, compared with fluconazole
administered at a dosage of 400 mg daily, and was associated
with a trend toward lower rates of aspergillosis [128]. After
transplantation, posaconazole was shown to be more effective
than fluconazole in preventing invasive fungal infections in
stem cell transplant recipients who had severe graft-versus-host
disease [126]. A recently completed randomized, double-blind
study that compared fluconazole (400 mg daily) with voricon-
azole (200 mg twice daily) for 100 days after transplantation
as primary antifungal prophylaxis in allogeneic stem cell trans-
plant recipients demonstrated no significant differences in the
incidence of invasive fungal infection or fungus-free survival
[294]. The usefulness of other potentially active agents, such
as itraconazole and AmB, in stem cell transplant recipients is
limited by toxicity, drug-drug interactions, logistical issues, or
bioavailability [295]. The optimal duration of prophylaxis is
not known but should, at a minimum, include the period of
risk of neutropenia.
PERFORMANCE MEASURES
1. All patients with candidemia should undergo a dilated
ophthalmological evaluation to exclude Candida endophthal-
mitis. This procedure has direct therapeutic implications, be-
cause patients with endophthalmitis may require surgery and
local therapy, and patients with disseminated disease require
longer courses of systemic therapy. We suggest that this be
performed at a time when the candidemia appears to be con-
trolled and when new spread to the eye is unlikely. Neutropenic
patients may not manifest visible endophthalmitis until recov-
ery from neutropenia; therefore, ophthalmological examination
in neutropenic patients should be performed after recovery of
the neutrophil count.
2. Antifungal therapy should be started on all candidemic
patients within 24 h after a blood culture positive for yeast.
Recent studies stress the importance of addressing a positive
blood culture result with prompt initiation of systemic anti-
fungal therapy, because delays are associated with increased
mortality.
Follow-up blood cultures should be obtained for all patients
with candidemia to ensure clearance of Candida from the
bloodstream. The Expert Panel recommends that blood cultures
be performed daily or every other day until they no longer
yield yeast.
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